Ttt of diabetes (bnf may 2012)
Upcoming SlideShare
Loading in...5
×
 

Ttt of diabetes (bnf may 2012)

on

  • 1,714 views

 

Statistics

Views

Total Views
1,714
Views on SlideShare
1,714
Embed Views
0

Actions

Likes
1
Downloads
54
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Ttt of diabetes (bnf may 2012) Ttt of diabetes (bnf may 2012) Document Transcript

  • British National FormularyBNF 61 March 2011
  • 418 BNF 61 6 Endocrine system 6.1 Drugs used in diabetes 418 6.7.3 Metyrapone and trilostane 482 6.1.1 Insulins 419 6.7.4 Somatomedins 483 6.1.1.1 Short-acting insulins 422 This chapter also includes advice on the drug man- 6.1.1.2 Intermediate- and long-acting agement of the following: insulins 423 Adrenal suppression during illness, trauma or 6.1.1.3Hypodermic equipment 426 surgery, p. 444 Serious infections in patients taking corticoster- 6.1.2Antidiabetic drugs 427 oids, p. 444 6.1.2.1Sulfonylureas 427 Osteoporosis, p. 469 Breast pain (mastalgia), p. 482 6.1.2.2Biguanides 429 6.1.2.3Other antidiabetic drugs 430 6.1.3Diabetic ketoacidosis 435 For hormonal contraception, see section 7.3. 6.1.4Treatment of hypoglycaemia 435 6.1.5Treatment of diabetic nephropa-6 Endocrine system thy and neuropathy 436 6.1.6 Diagnostic and monitoring 6.1 Drugs used in diabetes devices for diabetes mellitus 437 6.1.1 Insulins 6.2 Thyroid and antithyroid drugs 439 6.1.2 Antidiabetic drugs 6.2.1 Thyroid hormones 439 6.1.3 Diabetic ketoacidosis 6.2.2 Antithyroid drugs 440 6.1.4 Treatment of hypoglycaemia 6.1.5 Treatment of diabetic nephropathy 6.3 Corticosteroids 442 and neuropathy 6.3.1 Replacement therapy 442 6.1.6 Diagnostic and monitoring devices for 6.3.2 Glucocorticoid therapy 442 diabetes mellitus 6.4 Sex hormones 449 Diabetes mellitus occurs because of a lack of insulin or 6.4.1 Female sex hormones 449 resistance to its action. It is diagnosed by measuring 6.4.1.1 Oestrogens and HRT 449 fasting or random blood-glucose concentration (and occasionally by oral glucose tolerance test). Although 6.4.1.2 Progestogens 456 there are many subtypes, the two principal classes of 6.4.2 Male sex hormones and antago- diabetes are type 1 diabetes and type 2 diabetes. nists 458 Type 1 diabetes, (formerly referred to as insulin-depen- 6.4.3 Anabolic steroids 461 dent diabetes mellitus (IDDM)), occurs as a result of a deficiency of insulin following autoimmune destruction 6.5 Hypothalamic and pituitary hor- of pancreatic beta cells. Patients with type 1 diabetes mones and anti-oestrogens 461 require administration of insulin. 6.5.1 Hypothalamic and anterior pitui- Type 2 diabetes, (formerly referred to as non-insulin- tary hormones and anti-oestro- dependent diabetes (NIDDM)), is due to reduced secre- gens 461 tion of insulin or to peripheral resistance to the action of insulin or to a combination of both. Although patients 6.5.2 Posterior pituitary hormones and may be controlled on diet alone, many also require oral antagonists 466 antidiabetic drugs or insulin (or both) to maintain satis- 6.6 Drugs affecting bone metab- factory control. In overweight individuals, type 2 dia- betes may be prevented by losing weight and increasing olism 469 physical activity; use of the anti-obesity drug orlistat 6.6.1 Calcitonin and parathyroid (section 4.5.1) may be considered in obese patients. hormone 470 6.6.2 Bisphosphonates and other Treatment of diabetes Treatment of all forms of diabetes should be aimed at alleviating symptoms and drugs affecting bone metabolism 471 minimising the risk of long-term complications (see 6.7 Other endocrine drugs 477 below); tight control of diabetes is essential. 6.7.1 Bromocriptine and other Diabetes is a strong risk factor for cardiovascular dis- dopaminergic drugs 477 ease (section 2.12). Other risk factors for cardiovascular disease such as smoking (section 4.10.2), hypertension 6.7.2 Drugs affecting gonadotrophins 479 (section 2.5), obesity (section 4.5), and hyperlipidaemia
  • BNF 61 6.1.1 Insulins 419(section 2.12) should be addressed. Cardiovascular risk Driving Drivers with diabetes are required to notify thein patients with diabetes can be further reduced by the Driver and Vehicle Licensing Agency (DVLA) of theiruse of an ACE inhibitor (section 2.5.5.1), low-dose condition if they are treated with insulin or if they areaspirin (section 2.9) and a lipid-regulating drug (section treated with oral antidiabetic drugs and also have com-2.12). plications. Detailed guidance on eligibility to drive is available from the DVLA (www.dvla.gov.uk/Prevention of diabetic complications Optimal medical.aspx). Driving is not permitted when hypogly-glycaemic control in both type 1 diabetes and type 2 caemic awareness is impaired or frequent hypoglycae-diabetes reduces, in the long term, the risk of micro- mic episodes occur.vascular complications including retinopathy, develop- Drivers need to be particularly careful to avoid hypo-ment of proteinuria and to some extent neuropathy. glycaemia (see also above) and should be warned of theHowever, a temporary deterioration in established dia- problems. Drivers treated with insulin should normallybetic retinopathy may occur when normalising blood- check their blood-glucose concentration before drivingglucose concentration. For reference to the use of an and, on long journeys, at 2-hour intervals; these pre-ACE inhibitor or an angiotensin-II receptor antagonist in cautions may also be necessary for drivers taking oralthe management of diabetic nephropathy, see section antidiabetic drugs who are at particular risk of hypo-6.1.5. glycaemia. Drivers treated with insulin should ensureA measure of the total glycosylated (or glycated) hae- that a supply of sugar is always available in the vehiclemoglobin (HbA1 ) or a specific fraction (HbA1c ) provides and they should avoid driving if their meal is delayed. Ifa good indication of glycaemic control over the previous hypoglycaemia occurs, or warning signs develop, the2–3 months. Overall it is ideal to aim for an HbA1c driver should:(glycosylated haemoglobin) concentration of 48– . stop the vehicle in a safe place;59 mmol/mol (6.5–7.5%) or less (reference range 20– . switch off the ignition;42 mmol/mol or 4–6%) but this cannot always beachieved and for those using insulin there is a signifi- . eat or drink a suitable source of sugar;cantly increased risk of disabling hypoglycaemia; in . wait until recovery is complete before continuingthose at risk of arterial disease, the aim should be to journey; recovery may take 15 minutes or longermaintain the HbA1c concentration at 48 mmol/mol and should preferably be confirmed by checking(6.5%) or less. HbA1c should be measured every 3–6 blood-glucose concentration.months. Measurement of HbA1c HbA1c values currently expressed as a percentage, are aligned to the assay used in the Diabetes Con- 6 Endocrine system trol and Complications Trial (DCCT). A new stan- dard, specific for HbA1c , has been created by the 6.1.1 Insulins International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), which expresses 6.1.1.1 Short-acting insulins HbA1c values in mmol of glycosylated haemoglobin 6.1.1.2 Intermediate- and long-acting insulins per mol of haemoglobin. UK laboratories now 6.1.1.3 Hypodermic equipment express results in both IFCC-standardised units (mmol/mol) and DCCT-aligned units (%). From 1 June 2011, results will only be reported in IFCC- Insulin plays a key role in the regulation of carbohy- standardised units. drate, fat, and protein metabolism. It is a polypeptide hormone of complex structure. There are differences in the amino-acid sequence of animal insulins, human Equivalent values insulins and the human insulin analogues. Insulin may IFCC-HbA1c (mmol/mol) DCCT-HbA1c (%) be extracted from pork pancreas and purified by crystal- lisation; it may also be extracted from beef pancreas, but 42 6.0 beef insulins are now rarely used. Human sequence 48 6.5 insulin may be produced semisynthetically by enzy- matic modification of porcine insulin (emp) or bio- 53 7.0 synthetically by recombinant DNA technology using 59 7.5 bacteria (crb, prb) or yeast (pyr). 64 8.0 All insulin preparations are to a greater or lesser extent immunogenic in man but immunological resistance to 75 9.0 insulin action is uncommon. Preparations of human sequence insulin should theoretically be less immuno-Laboratory measurement of serum-fructosamine con- genic, but no real advantage has been shown in trials.centration is technically simpler and cheaper than the Insulin is inactivated by gastro-intestinal enzymes, andmeasurement of HbA1c and can be used to assess must therefore be given by injection; the subcutaneouscontrol over short periods of time, particularly when route is ideal in most circumstances. Insulin is usuallyHbA1c monitoring is invalid (e.g. disturbed erythrocyte injected into the upper arms, thighs, buttocks, or abdo-turnover or abnormal haemoglobin type). men; absorption from a limb site may be increased if theTight control of blood pressure in hypertensive patients limb is used in strenuous exercise after the injection.with type 2 diabetes reduces mortality and protects Generally subcutaneous insulin injections cause fewvisual acuity (by reducing considerably the risks of problems; lipodystrophy may occur but can be mini-maculopathy and retinal photocoagulation) (see also mised by using different injection sites in rotation. Localsection 2.5). allergic reactions are rare.
  • 420 6.1.1 Insulins BNF 61 Insulin is needed by all patients with ketoacidosis, and it with certain endocrine disorders (e.g. Addison’s disease, is likely to be needed by most patients with: hypopituitarism), or in coeliac disease. . rapid onset of symptoms; . substantial loss of weight; Examples of recommended insulin regimens . weakness; . Multiple injection regimen: short-acting insulin or . ketonuria; rapid-acting insulin analogue, before meals . a first-degree relative who has type 1 diabetes. With intermediate-acting or long-acting insulin, once or twice daily; Insulin is required by almost all children with diabetes. It is also needed for type 2 diabetes when other methods . Short-acting insulin or rapid-acting insulin analogue have failed to achieve good control, and temporarily in mixed with intermediate-acting or long-acting insu- the presence of intercurrent illness or peri-operatively. lin, once or twice daily (before meals); Pregnant women with type 2 diabetes may be treated . Intermediate-acting or long-acting insulin, once or with insulin when diet alone fails. For advice on use of twice daily oral antidiabetic drugs in the management of diabetes in With or without short-acting insulin or rapid-acting pregnancy, see section 6.1.2. insulin before meals; . Continuous subcutaneous insulin infusion (see NHS Diabetes guidance below). Safe and Effective Use of Insulin in Hospitalised Patients (March 2010) Available at www.diabetes.nhs.uk Hepatic impairment Insulin requirements may be decreased in patients with hepatic impairment. Management of diabetes with insulin The aim of6 Endocrine system treatment is to achieve the best possible control of Renal impairment Insulin requirements may fall in blood-glucose concentration without making the patient patients with renal impairment and therefore dose obsessional and to avoid disabling hypoglycaemia; close reduction may be necessary. The compensatory co-operation is needed between the patient and the response to hypoglycaemia is impaired in renal impair- medical team because good control reduces the risk of ment. complications. Insulin preparations can be divided into 3 types: Pregnancy and breast-feeding During pregnancy . those of short duration which have a relatively and breast-feeding, insulin requirements may alter and rapid onset of action, namely soluble insulin and doses should be assessed frequently by an experienced the rapid-acting insulin analogues, insulin aspart, diabetes physician. The dose of insulin generally needs insulin glulisine, and insulin lispro (section 6.1.1.1); to be increased in the second and third trimesters of . those with an intermediate action, e.g. isophane pregnancy. The short-acting insulin analogues, insulin insulin (section 6.1.1.2); and aspart and insulin lispro, are not known to be harmful, and may be used during pregnancy and lactation. The . those whose action is slower in onset and lasts for safety of long-acting insulin analogues in pregnancy has long periods, e.g. protamine zinc insulin, insulin not been established, therefore isophane insulin is detemir, and insulin glargine (section 6.1.1.2). recommended where longer-acting insulins are needed. The duration of action of a particular type of insulin varies considerably from one patient to another, and needs to be assessed individually. Insulin administration Insulin is generally given by Mixtures of insulin preparations may be required and subcutaneous injection; the injection site should be appropriate combinations have to be determined for the rotated to prevent lipodystrophy. Injection devices individual patient. Treatment should be started with a (‘pens’) (section 6.1.1.3), which hold the insulin in a short-acting insulin (e.g. soluble insulin) or a rapid-act- cartridge and meter the required dose, are convenient ing insulin analogue (e.g. insulin aspart) given before to use. Insulin syringes (for use with needles) are meals with intermediate-acting or long-acting insulin required for insulins not available in cartridge form. once or twice daily. Alternatively, for those who have For intensive insulin regimens multiple subcutaneous difficulty with, or prefer not to use, multiple injection injections (3 or more times daily) are usually recom- regimens, a mixture of premixed short-acting insulin or mended. rapid acting insulin analogue with an intermediate-act- Short-acting injectable insulins (soluble insulin, insulin ing or long-acting insulin (most commonly in a propor- aspart, insulin glulisine, and insulin lispro) can also be tion of 30% soluble insulin and 70% isophane insulin) given by continuous subcutaneous infusion using a can be given once or twice daily. The dose of short- portable infusion pump. This device delivers a contin- acting or rapid-acting insulin (or the proportion of the uous basal insulin infusion and patient-activated bolus short-acting soluble insulin component in premixed doses at meal times. This technique can be useful for insulin) can be increased in those with excessive post- patients who suffer recurrent hypoglycaemia or marked prandial hyperglycaemia. The dose of insulin is morning rise in blood-glucose concentration despite increased gradually according to the patient’s individual optimised multiple-injection regimens (see also NICE requirements, taking care to avoid troublesome hypo- guidance, below). Patients on subcutaneous insulin infu- glycaemic reactions. sion must be highly motivated, able to monitor their Insulin requirements may be increased by infection, blood-glucose concentration, and have expert training, stress, accidental or surgical trauma, and during advice and supervision from an experienced healthcare puberty. Requirements may be decreased in those team.
  • BNF 61 6.1.1 Insulins 421 ment of insulin type, dose and frequency together with NICE guidance suitable timing and quantity of meals and snacks. Continuous subcutaneous insulin infusion Some patients have reported loss of hypoglycaemia for the treatment of diabetes mellitus (type warning after transfer to human insulin. Clinical studies 1) (July 2008) do not confirm that human insulin decreases hypoglyc- Continuous subcutaneous insulin infusion is recom- aemia awareness. If a patient believes that human insu- mended as an option in adults and children over 12 lin is responsible for the loss of warning it is reasonable years with type 1 diabetes: to revert to animal insulin and essential to educate the . who suffer repeated or unpredictable hypoglyc- patient about avoiding hypoglycaemia. Great care aemia, whilst attempting to achieve optimal should be taken to specify whether a human or an glycaemic control with multiple-injection regi- animal preparation is required. mens, or . whose glycaemic control remains inadequate Few patients are now treated with beef insulins; when (HbA1c over 8.5%) despite optimised multiple- undertaking conversion from beef to human insulin, the injection regimens (including the use of long- total dose should be reduced by about 10% with careful acting insulin analogues where appropriate). monitoring for the first few days. When changing between pork and human-sequence insulins, a dose Continuous subcutaneous insulin infusion is also change is not usually needed, but careful monitoring is recommended as an option for children under 12 still advised. years with type 1 diabetes for whom multiple-injec- tion regimens are considered impractical or inap- propriate. Children on insulin pumps should undergo Diabetes and surgery Perioperative control of blood- a trial of multiple-injection therapy between the ages glucose concentrations in patients with type 1 diabetes of 12 and 18 years. is achieved via an adjustable, continuous, intravenous infusion of insulin. Detailed local protocols should beSoluble insulin by the intravenous route is reserved for available to all healthcare professionals involved in theurgent treatment, e.g. in diabetic ketoacidosis, and for treatment of these patients; in general, the followingfine control in serious illness and in the peri-operative steps should be followed:period (see under Diabetes and Surgery, below). . Give an injection of the patient’s usual insulin on the night before the operation;Units The word ‘unit’ should not be abbreviated. . Early on the day of the operation, start an intra- venous infusion of glucose containing potassiumMonitoring Many patients now monitor their own chloride (provided that the patient is not hyperka-blood-glucose concentrations (section 6.1.6). Since laemic) and infuse at a constant rate appropriate toblood-glucose concentration varies substantially the patient’s fluid requirements (usually 125 mL per 6 Endocrine systemthroughout the day, ‘normoglycaemia’ cannot always hour); make up a solution of soluble insulin in sod-be achieved throughout a 24-hour period without caus- ium chloride 0.9% and infuse intravenously using aing damaging hypoglycaemia. It is therefore best to syringe pump piggy-backed to the intravenous infu-recommend that patients should maintain a blood-glu- sion. Glucose and potassium infusions, and insulincose concentration of between 4 and 9 mmol/litre for infusions should be made up according to locallymost of the time (4–7 mmol/litre before meals and less agreed protocols;than 9 mmol/litre after meals), while accepting that onoccasions, for brief periods, it will be above these values; . The rate of the insulin infusion should be adjustedstrenuous efforts should be made to prevent the blood- according to blood-glucose concentration (frequentglucose concentration from falling below 4 mmol/litre. monitoring necessary) in line with locally agreedPatients using multiple injection regimens should under- protocols. Other factors affecting the rate of infu-stand how to adjust their insulin dose according to their sion include the patient’s volume depletion, cardiaccarbohydrate intake. With fixed-dose insulin regimens, function, and age.the carbohydrate intake needs to be regulated, and Protocols should include specific instructions on how toshould be distributed throughout the day to match the manage resistant cases (such as patients who are ininsulin regimen. The intake of energy and of simple and shock or severely ill or those receiving corticosteroids orcomplex carbohydrates should be adequate to allow sympathomimetics) and those with hypoglycaemia.normal growth and development but obesity must be If a syringe pump is not available, soluble insulin shouldavoided. be added to the intravenous infusion of glucose and potassium chloride (provided the patient is not hyper-Hypoglycaemia Hypoglycaemia is a potential pro- kalaemic), and the infusion run at the rate appropriate toblem with insulin therapy. All patients must be carefully the patient’s fluid requirements (usually 125 mL perinstructed on how to avoid it. hour) with the insulin dose adjusted according toLoss of warning of hypoglycaemia among insulin-trea- blood-glucose concentration in line with locally agreedted patients can be a serious hazard, especially for protocols.drivers and those in dangerous occupations. Very tight Once the patient starts to eat and drink, give subcuta-control of diabetes lowers the blood-glucose concentra- neous insulin before breakfast and stop intravenoustion needed to trigger hypoglycaemic symptoms; an insulin 30 minutes later; the dose may need to be 10–increase in the frequency of hypoglycaemic episodes 20% more than usual if the patient is still in bed ormay reduce the warning symptoms experienced by the unwell. If the patient was not previously receiving insu-patient. Beta-blockers can also blunt hypoglycaemic lin, an appropriate initial dose is 30–40 units daily in fourawareness (and also delay recovery). divided doses using soluble insulin before meals andTo restore the warning signs, episodes of hypoglycaemia intermediate-acting insulin at bedtime and the dosemust be minimised; this involves appropriate adjust- adjusted from day to day. Patients with hyperglycaemia
  • 422 6.1.1 Insulins BNF 61 often relapse after conversion back to subcutaneous Dose insulin calling for one of the following approaches: . By subcutaneous, intramuscular or intravenous . additional doses of soluble insulin at any of the four injection or intravenous infusion, according to injection times (before meals or bedtime) or requirements . temporary addition of intravenous insulin infusion Highly purified animal (while continuing the subcutaneous regimen) until Counselling Show container to patient and confirm that blood-glucose concentration is satisfactory or patient is expecting the version dispensed . complete reversion to the intravenous regimen Hypurin c Bovine Neutral (Wockhardt) A (especially if the patient is unwell). Injection, soluble insulin (bovine, highly purified) 100 units/mL. Net price 10-mL vial = £18.48; car- tridges (for Autopen c Classic) 5 Â 3 mL = £27.72 6.1.1.1 Short-acting insulins Hypurin c Porcine Neutral (Wockhardt) A Injection, soluble insulin (porcine, highly purified) Soluble insulin is a short-acting form of insulin. For 100 units/mL. Net price 10-mL vial = £16.80; car- maintenance regimens it is usual to inject it 15 to 30 tridges (for Autopen c Classic) 5 Â 3 mL = £25.20 minutes before meals. Soluble insulin is the most appropriate form of insulin Human sequence for use in diabetic emergencies e.g. diabetic ketoacid- Counselling Show container to patient and confirm that patient is expecting the version dispensed osis (section 6.1.3) and at the time of surgery. It can be given intravenously and intramuscularly, as well as sub- Actrapid c (Novo Nordisk) A cutaneously. Injection, soluble insulin (human, pyr) 100 units/mL. When injected subcutaneously, soluble insulin has a Net price 10-mL vial = £7.48 rapid onset of action (30 to 60 minutes), a peak action Note Not recommended for use in subcutaneous insulin infusion6 Endocrine system pumps—may precipitate in catheter or needle between 2 and 4 hours, and a duration of action of up to 8 hours. Humulin S c (Lilly) A When injected intravenously, soluble insulin has a very Injection, soluble insulin (human, prb) 100 units/mL. short half-life of only about 5 minutes and its effect Net price 10-mL vial = £15.68; 5 Â 3-mL cartridge (for disappears within 30 minutes. most Autopen c Classic or HumaPen c ) = £19.08 The rapid-acting human insulin analogues, insulin Insuman c Rapid (Sanofi-Aventis) A aspart, insulin glulisine, and insulin lispro have a Injection, soluble insulin (human, crb) 100 units/mL, faster onset and shorter duration of action than soluble net price 5 Â 3-mL cartridge (for ClikSTAR c and insulin; as a result, compared to soluble insulin, fasting OptiPen c Pro 1) = £17.50; 5 Â 3-mL Insuman c and preprandial blood-glucose concentrations are a Rapid OptiSet c prefilled disposable injection devices little higher, postprandial blood-glucose concentration (range 2–40 units, allowing 2-unit dosage adjustment) is a little lower, and hypoglycaemia occurs slightly less = £17.50 frequently. Subcutaneous injection of insulin analogues Note Not recommended for use in subcutaneous insulin infusion pumps may be convenient for those who wish to inject shortly before or, when necessary, shortly after a meal. They can also help those susceptible to hypoglycaemia before Mixed preparations lunch and those who eat late in the evening and are See Biphasic Isophane Insulin (section 6.1.1.2) prone to nocturnal hypoglycaemia. They can also be administered by subcutaneous infusion (see Insulin Administration, above). Insulin aspart and insulin lispro INSULIN ASPART can be administered intravenously and can be used as (Recombinant human insulin analogue) alternatives to soluble insulin for diabetic emergencies Indications diabetes mellitus and at the time of surgery. Cautions section 6.1.1; interactions: Appendix 1 (antidiabetics) INSULIN Hepatic impairment section 6.1.1 (Insulin Injection; Neutral Insulin; Soluble Renal impairment section 6.1.1 Insulin) Pregnancy section 6.1.1 A sterile solution of insulin (i.e. bovine or porcine) or Breast-feeding section 6.1.1 of human insulin; pH 6.6–8.0 Side-effects see under Insulin Indications diabetes mellitus; diabetic ketoacidosis Dose (section 6.1.3) . By subcutaneous injection, ADULT and CHILD over 2 Cautions section 6.1.1; interactions: Appendix 1 years, immediately before meals or when necessary (antidiabetics) shortly after meals, according to requirements Hepatic impairment section 6.1.1 . By subcutaneous infusion, intravenous injection or Renal impairment section 6.1.1 intravenous infusion, ADULT and CHILD over 2 years, Pregnancy section 6.1.1 according to requirements Breast-feeding section 6.1.1 NovoRapid c (Novo Nordisk) A Side-effects see notes above; transient oedema; local Injection, insulin aspart (recombinant human insulin reactions and fat hypertrophy at injection site; rarely analogue) 100 units/mL, net price 10-mL vial = hypersensitivity reactions including urticaria, rash; £16.28; Penfill c cartridge (for NovoPen c devices) 5 Â overdose causes hypoglycaemia 3-mL = £28.84; 5 Â 3-mL FlexPen c prefilled
  • BNF 61 6.1.1 Insulins 423 disposable injection devices (range 1–60 units, allow- 5 Â 3-mL Humalog c KwikPen prefilled disposable ing 1-unit dosage adjustment) = £32.00 injection devices (range 1–60 units, allowing 1-unit Counselling Show container to patient and confirm that dosage adjustment) = £29.46 patient is expecting the version dispensed Counselling Show container to patient and confirm that patient is expecting the version dispensed INSULIN GLULISINE (Recombinant human insulin analogue) 6.1.1.2 Intermediate- and long-actingIndications diabetes mellitus insulinsCautions section 6.1.1; interactions: Appendix 1 (antidiabetics) When given by subcutaneous injection, intermediate-Hepatic impairment section 6.1.1 and long-acting insulins have an onset of action ofRenal impairment section 6.1.1 approximately 1–2 hours, a maximal effect at 4–12Pregnancy section 6.1.1 hours, and a duration of 16–35 hours. Some are givenBreast-feeding section 6.1.1 twice daily in conjunction with short-acting (soluble)Side-effects see under Insulin insulin, and others are given once daily, particularly inDose elderly patients. Soluble insulin can be mixed with. By subcutaneous injection, ADULT and CHILD over 6 intermediate and long-acting insulins (except insulin years, immediately before meals or when necessary detemir and insulin glargine) in the syringe, essentially shortly after meals, according to requirements retaining the properties of the two components, although there may be some blunting of the initial effect. By subcutaneous infusion, or intravenous infusion of the soluble insulin component (especially on mixing ADULT and CHILD over 6 years, according to require- with protamine zinc insulin, see below). ments Isophane insulin is a suspension of insulin with prot-Apidra c (Sanofi-Aventis) A amine; it is of particular value for initiation of twice-daily Injection, insulin glulisine (recombinant human insu- insulin regimens. Patients usually mix isophane with lin analogue) 100 units/mL, net price 10-mL vial = soluble insulin but ready-mixed preparations may be £16.60; 5Â 3-mL cartridge (for ClikSTAR c , OptiPen c appropriate (biphasic isophane insulin, biphasic insu- Pro 1, and Autopen c 24) = £28.30; 5 Â 3-mL lin aspart, or biphasic insulin lispro). OptiClik c cartridge (for OptiClik c Pen) = £30.27; 5 Â 3-mL Apidra c Optiset c prefilled disposable injection Insulin zinc suspension (30% amorphous, 70% cryst- devices (range 2–40 units, allowing 2-unit dosage alline) has a more prolonged duration of action. adjustment) = £28.30; 5 Â 3-mL Apidra c SoloStar c Protamine zinc insulin is usually given once daily with prefilled disposable injection devices (range 1– short-acting (soluble) insulin. It has the drawback of 6 Endocrine system 80 units, allowing 1-unit dosage adjustment) = £25.00 binding with the soluble insulin when mixed in theCounselling Show container to patient and confirm that same syringe and is now rarely used.patient is expecting the version dispensedNote The Scottish Medicines Consortium (p. 4) has advised Insulin glargine and insulin detemir are both long-(October 2008) that Apidra c is accepted for restricted use acting human insulin analogues with a prolonged dura-within NHS Scotland for the treatment of adults and children tion of action; insulin glargine is given once daily andover 6 years with diabetes mellitus in whom the use of a short- insulin detemir is given once or twice daily. NICEacting insulin analogue is appropriate (December 2002) has recommended that insulin glar- gine should be available as an option for patients with INSULIN LISPRO type 1 diabetes. (Recombinant human insulin analogue) NICE (May 2009) has recommended that, if insulin isIndications diabetes mellitus required in patients with type 2 diabetes, insulin detemirCautions section 6.1.1; children (use only if benefit or insulin glargine may be considered for those: likely compared to soluble insulin); interactions: . who require assistance with injecting insulin or Appendix 1 (antidiabetics) . whose lifestyle is significantly restricted by recur-Hepatic impairment section 6.1.1 rent symptomatic hypoglycaemia orRenal impairment section 6.1.1 . who would otherwise need twice-daily basal insulinPregnancy section 6.1.1 injections in combination with oral antidiabeticBreast-feeding section 6.1.1 drugs orSide-effects see under Insulin . who cannot use the device needed to inject iso-Dose phane insulin.. By subcutaneous injection shortly before meals or when necessary shortly after meals, according to requirements. By subcutaneous infusion, or intravenous injection, INSULIN DETEMIR (Recombinant human insulin analogue—long or intravenous infusion, according to requirements acting)Humalog (Lilly) A c Indications diabetes mellitus Injection, insulin lispro (recombinant human insulin analogue) 100 units/mL, net price 10-mL vial = Cautions section 6.1.1.1; interactions: Appendix 1 £16.61; 5 Â 3-mL cartridge (for Autopen c Classic or (antidiabetics) HumaPen c ) = £28.31; 5 Â 3-mL Humalog c -Pen Hepatic impairment section 6.1.1 prefilled disposable injection devices (range 1– Renal impairment section 6.1.1 60 units, allowing 1-unit dosage adjustment) = £29.46; Pregnancy section 6.1.1
  • 424 6.1.1 Insulins BNF 61 Breast-feeding section 6.1.1 Hepatic impairment section 6.1.1 Side-effects see under Insulin (section 6.1.1.1) Renal impairment section 6.1.1 Dose Pregnancy section 6.1.1 . By subcutaneous injection, ADULT and CHILD over 6 Breast-feeding section 6.1.1 years, according to requirements Side-effects see under Insulin (section 6.1.1.1) Levemir c (Novo Nordisk) A Dose Injection, insulin detemir (recombinant human insulin . By subcutaneous injection, according to require- analogue) 100 units/mL, net price 5 Â 3-mL cartridge ments (for NovoPen c devices) = £42.00; 5 Â 3-mL FlexPen c prefilled disposable injection device (range 1–60 units, Highly purified animal allowing 1-unit dosage adjustment) = £42.00; 5 Â 3- Hypurin c Bovine Lente (Wockhardt) A mL Levemir InnoLet c prefilled disposable injection Injection, insulin zinc suspension (bovine, highly devices (range 1–50 units, allowing 1-unit dosage purified) 100 units/mL. Net price 10-mL vial = £27.72 adjustment) = £44.85 Counselling Show container to patient and confirm that patient is expecting the version dispensed Counselling Show container to patient and confirm that patient is expecting the version dispensed ISOPHANE INSULIN INSULIN GLARGINE (Isophane Insulin Injection; Isophane Prot- (Recombinant human insulin analogue—long amine Insulin Injection; Isophane Insulin acting) (NPH)—intermediate acting) A sterile suspension of bovine or porcine insulin or of human Indications diabetes mellitus insulin in the form of a complex obtained by the addition of Cautions section 6.1.1.1; interactions: Appendix 1 protamine sulphate or another suitable protamine (antidiabetics) Indications diabetes mellitus Hepatic impairment section 6.1.16 Endocrine system Cautions section 6.1.1.1; interactions: Appendix 1 Renal impairment section 6.1.1 (antidiabetics) Pregnancy section 6.1.1 Hepatic impairment section 6.1.1 Breast-feeding section 6.1.1 Renal impairment section 6.1.1 Side-effects see under Insulin (section 6.1.1.1) Pregnancy section 6.1.1 Dose Breast-feeding section 6.1.1 . By subcutaneous injection, ADULT and CHILD over 6 Side-effects see under Insulin (section 6.1.1.1); prot- years, according to requirements amine may cause allergic reactions Lantus c (Sanofi-Aventis) A Dose Injection, insulin glargine (recombinant human insu- . By subcutaneous injection, according to require- lin analogue) 100 units/mL, net price 10-mL vial = ments £26.00; 5 Â 3-mL cartridge (for ClikSTAR c , OptiPen c Pro 1, and Autopen c 24) = £39.00; 5 Â 3- Highly purified animal mL OptiClik c cartridge (for OptiClik c Pen) = £40.36; Counselling Show container to patient and confirm that patient is expecting the version dispensed 5 Â 3-mL Lantus c OptiSet c prefilled disposable injection devices (range 2–40 units, allowing 2-unit Hypurin c Bovine Isophane (Wockhardt) A dosage adjustment) = £39.00; 5 Â 3-mL Lantus c Injection, isophane insulin (bovine, highly purified) SoloStar c prefilled disposable injection devices 100 units/mL. Net price 10-mL vial = £27.72; car- (range 1–80 units, allowing 1-unit dosage adjustment) tridges (for Autopen c Classic) 5 Â 3 mL = £41.58 = £40.36 Note The Scottish Medicines Consortium (p. 4) has advised Hypurin c Porcine Isophane (Wockhardt) A (October 2002) that insulin glargine is accepted for restricted Injection, isophane insulin (porcine, highly purified) use within NHS Scotland for the treatment of type 1 diabetes: 100 units/mL. Net price 10-mL vial = £25.20; car- . in those who are at risk of or experience unacceptable tridges (for Autopen c Classic) 5 Â 3 mL = £37.80 frequency or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control Human sequence during treatment with other insulins Counselling Show container to patient and confirm that . as a once daily insulin therapy for patients who require a patient is expecting the version dispensed carer to administer their insulin. It is not recommended for routine use in patients with type 2 Insulatardc (Novo Nordisk) A diabetes unless they suffer from recurrent episodes of Injection, isophane insulin (human, pyr) 100 units/ hypoglycaemia or require assistance with their insulin mL. Net price 10-mL vial = £7.48; Insulatard Penfill c injections. cartridge (for Novopen c devices) 5 Â 3 mL = £22.90; Counselling Show container to patient and confirm that patient is expecting the version dispensed 5 Â 3-mL Insulatard InnoLet c prefilled disposable injection devices (range 1–50 units, allowing 1-unit dosage adjustment) = £20.40 INSULIN ZINC SUSPENSION (Insulin Zinc Suspension (Mixed)—long acting) Humulin I c (Lilly) A A sterile neutral suspension of bovine and/or porcine insulin or Injection, isophane insulin (human, prb) 100 units/ of human insulin in the form of a complex obtained by the mL. Net price 10-mL vial = £15.68; 5 Â 3-mL cartridge addition of a suitable zinc salt; consists of rhombohedral (for Autopen c Classic or HumaPen c ) = £19.08; 5 Â crystals (10–40 microns) and of particles of no uniform shape 3-mL Humulin I-Pen c prefilled disposable injection (not exceeding 2 microns) devices (range 1–60 units, allowing 1-unit dosage Indications diabetes mellitus adjustment) = £28.44; 5 Â 3-mL Humulin I KwikPen c Cautions section 6.1.1.1; interactions: Appendix 1 prefilled disposable injection devices (range 1– (antidiabetics) 60 units, allowing 1-unit dosage adjustment) = £21.70
  • BNF 61 6.1.1 Insulins 425Insuman c Basal (Sanofi-Aventis) A BIPHASIC INSULIN LISPRO Injection, isophane insulin (human, crb) 100 units/ (Intermediate-acting insulin) mL, net price 5-mL vial = £5.61; 5 Â 3-mL cartridge (for ClikSTAR c and OptiPen c Pro 1) = £17.50; 5 Â 3- Indications diabetes mellitus mL Insuman c Basal OptiSet c prefilled disposable Cautions see section 6.1.1.1 and Insulin Lispro; injection devices (range 2–40 units, allowing 2-unit interactions: Appendix 1 (antidiabetics) dosage adjustment) = £17.50 Hepatic impairment section 6.1.1 Renal impairment section 6.1.1 Mixed preparations Pregnancy section 6.1.1 See Biphasic Isophane Insulin (below) Breast-feeding section 6.1.1 Side-effects see under Insulin (section 6.1.1.1); prot- PROTAMINE ZINC INSULIN amine may cause allergic reactions (Protamine Zinc Insulin Injection—long acting) DoseA sterile suspension of insulin in the form of a complex . By subcutaneous injection, up to 15 minutes before orobtained by the addition of a suitable protamine and zincchloride; this preparation was included in BP 1980 but is not soon after a meal, according to requirementsincluded in BP 1988 Humalog c Mix25 (Lilly) AIndications diabetes mellitus Injection, biphasic insulin lispro (recombinant humanCautions section 6.1.1.1; see also notes above; inter- insulin analogue), 25% insulin lispro, 75% insulin actions: Appendix 1 (antidiabetics) lispro protamine, 100 units/mL, net price 10-mL vialHepatic impairment section 6.1.1 = £16.61; 5 Â 3-mL cartridge (for Autopen c Classic orRenal impairment section 6.1.1 HumaPen c ) = £29.46; 5 Â 3-mL prefilled disposable injection devices (range 1–60 units, allowing 1-unitPregnancy section 6.1.1 dosage adjustment) = £30.98; 5 Â 3-mL Humalog cBreast-feeding section 6.1.1 Mix25 KwikPen prefilled disposable injection devicesSide-effects see under Insulin (section 6.1.1.1); prot- (range 1–60 units, allowing 1-unit dosage adjustment) amine may cause allergic reactions = £30.98Dose Counselling Show container to patient and confirm that. By subcutaneous injection, according to require- patient is expecting the version dispensed; the proportions of the two components should be checked carefully (the order ments in which the proportions are stated may not be the same inHypurin c Bovine Protamine Zinc (Wockhardt) A other countries) Injection, protamine zinc insulin (bovine, highly pur- Humalog c Mix50 (Lilly) A ified) 100 units/mL. Net price 10-mL vial = £27.72 Injection, biphasic insulin lispro (recombinant human 6 Endocrine system Counselling Show container to patient and confirm that patient is expecting the version dispensed insulin analogue), 50% insulin lispro, 50% insulin lispro protamine, 100 units/mL, net price 5 Â 3-mL cartridge (for Autopen c Classic or HumaPen c ) = £29.46; 5 Â 3-mL prefilled disposable injectionBiphasic insulins devices (range 1–60 units, allowing 1-unit dosage adjustment) = £29.46; 5 Â 3-mL Humalog c Mix50 KwikPen prefilled disposable injection devices (range BIPHASIC INSULIN ASPART 1–60 units, allowing 1-unit dosage adjustment) = (Intermediate-acting insulin) £30.98Indications diabetes mellitus Counselling Show container to patient and confirm that patient is expecting the version dispensed; the proportions ofCautions see section 6.1.1.1; interactions: Appendix 1 the two components should be checked carefully (the order (antidiabetics) in which the proportions are stated may not be the same inHepatic impairment section 6.1.1 other countries)Renal impairment section 6.1.1Pregnancy section 6.1.1Breast-feeding section 6.1.1 BIPHASIC ISOPHANE INSULINSide-effects see under Insulin (section 6.1.1.1); prot- (Biphasic Isophane Insulin Injection—inter- amine may cause allergic reactions mediate acting)Dose A sterile buffered suspension of either porcine or human insulin complexed with protamine sulphate (or another suitable prot-. By subcutaneous injection, up to 10 minutes before or amine) in a solution of insulin of the same species soon after a meal, according to requirements Indications diabetes mellitusNovoMix c 30 (Novo Nordisk) A Cautions section 6.1.1.1; interactions: Appendix 1 Injection, biphasic insulin aspart (recombinant (antidiabetics) human insulin analogue), 30% insulin aspart, 70% Hepatic impairment section 6.1.1 insulin aspart protamine, 100 units/mL, net price 5 Â Renal impairment section 6.1.1 3-mL Penfill c cartridges (for NovoPen c devices) = £28.84; 5 Â 3-mL FlexPen c prefilled disposable Pregnancy section 6.1.1 injection devices (range 1–60 units, allowing 1-unit Breast-feeding section 6.1.1 dosage adjustment) = £32.00 Side-effects see under Insulin (section 6.1.1.1); prot- Counselling Show container to patient and confirm that amine may cause allergic reactions patient is expecting the version dispensed; the proportions of Dose the two components should be checked carefully (the order in which the proportions are stated may not be the same in . By subcutaneous injection, according to require- other countries) ments
  • 426 6.1.1 Insulins BNF 61 Highly purified animal Injection devices Counselling Show container to patient and confirm that Autopen c (Owen Mumford) patient is expecting the version dispensed; the proportions of Injection device, Autopen c 24 (for use with Sanofi-Aventis the two components should be checked carefully (the order 3-mL insulin cartridges), allowing 1-unit dosage adjustment, in which the proportions are stated may not be the same in max. 21 units (single-unit version) or 2-unit dosage adjust- other countries) ment, max. 42 units (2-unit version), net price (both) = £15.73; Autopen c Classic (for use with Lilly and Wockhardt 3-mL insulin cartridges), allowing 1-unit dosage adjustment, Hypurin c Porcine 30/70 Mix (Wockhardt) A max. 21 units (single-unit version) or 2-unit dosage adjust- Injection, biphasic isophane insulin (porcine, highly ment, max. 42 units (2-unit version), net price (all) = £15.97 purified), 30% soluble, 70% isophane, 100 units/mL. ClikSTAR c (Sanofi-Aventis) Net price 10-mL vial = £16.80; cartridges (for Autop- Injection device, for use with Lantus c , Apidra c , and en c Classic) 5 Â 3 mL = £25.20 Insuman c 3-mL insulin cartridges; allowing 1-unit dose adjustment, max. 80 units, net price = £25.00 Human sequence HumaPen c Luxura (Lilly) Counselling Show container to patient and confirm that Injection device, for use with Humulin c and Humalog c 3- patient is expecting the version dispensed; the proportions of mL cartridges; allowing 1-unit dosage adjustment, max. the two components should be checked carefully (the order 60 units, net price = £26.36 in which the proportions are stated may not be the same in HumaPen c Luxura HD (Lilly) other countries) Injection device, for use with Humulin c and Humalog c 3- mL cartridges; allowing 0.5-unit dosage adjustment, max. Humulin M3 (Lilly) A c 30 units, net price = £26.36 Injection, biphasic isophane insulin (human, prb), NovoPenc (Novo Nordisk) 30% soluble, 70% isophane, 100 units/mL. Net price Injection device; for use with Penfill c insulin cartridges; 10-mL vial = £15.68; 5 Â 3-mL cartridge (for most NovoPen c Junior (for 3-mL cartridges), allowing 0.5-unit dosage adjustment, max. 35 units, net price = £24.79;6 Endocrine system Autopen c Classic or HumaPen c ) = £19.08; 5 Â 3-mL Humulin M3 KwikPen c prefilled disposable injection NovoPen c 3 Demi (for 3-mL cartridges), allowing 0.5-unit dosage adjustment, max. 35 units, net price = £25.21; devices (range 1–60 units, allowing 1-unit dosage NovoPen c 4 (for 3-mL cartridges), allowing 1-unit dosage adjustment) = £21.70 adjustment, max. 60 units, net price = £26.56 OptiClikc (Sanofi-Aventis) Insuman c Comb 15 (Sanofi-Aventis) A Injection device, for use with Lantus OptiClik c or Apidra Injection, biphasic isophane insulin (human, crb), Opticlik c insulin cartridges, allowing 1-unit dosage adjust- 15% soluble, 85% isophane, 100 units/mL, net price 5 ment, max. 80 units, net price = £20.13 Â 3-mL Insuman c Comb 15 OptiSet c prefilled OptiPen c Pro 1 (Sanofi-Aventis) disposable injection devices (range 2–40 units, allow- Injection device, for use with Insuman c insulin cartridges; ing 2-unit dosage adjustment) = £17.50 allowing 1-unit dosage adjustment, max. 60 units, net price = £22.00 Insuman c Comb 25 (Sanofi-Aventis) A Lancets Injection, biphasic isophane insulin (human, crb), Lancets—sterile, single use (Drug Tariff) 25% soluble, 75% isophane, 100 units/mL, net price 1 Ascensia Microlet c 100 = £3.76, 200 = £7.17; BD Micro- 5-mL vial = £5.61; 5 Â 3-mL cartridge (for ClikSTAR c Fine c + 100 = £3.16, 200 = £6.13; CareSens c 100 = £2.95; and OptiPen c Pro 1) = £17.50; 5 Â 3-mL Insuman c Cleanlet Fine c 100 = £3.19, 200 = £6.13; Fastclix c 204 = Comb 25 OptiSet c prefilled disposable injection £9.20; 1 Finepoint c 100 = £3.54; 1 FreeStyle c 200 = £7.02; 1 Milward Steri-Let c , 23 gauge, 100 = £3.00, 200 = £5.70, 28 devices (range 2–40 units, allowing 2-unit dosage gauge, 100 = £3.00, 200 = £5.70; 1 Monolet c 100 = £3.28, 200 adjustment) = £17.50; 5 Â 3-mL Insuman c Comb 25 = £6.24; Monolet Extra c 100 = £3.28; MPD Ultra Thin c 100 SoloStar c prefilled disposable injection devices = £3.30, 200 = £6.50; Multiclix c 204 = £9.27; One Touch (range 1–80 units, allowing 1-unit dosage adjustment) Comfort c 200 = £7.22; 1 One Touch UltraSoft c 100 = £3.61; 2 Softclix c 200 = £7.40; 2 Softclix XL c 50 = £1.85; Thin = £19.80 Lancets (formerly MediSense Thin c ), 200 = £7.16; 1 Unilet ComforTouch c 100 = £3.60, 200 = £6.83; Unilet Eco c 100 = £2.94, 200 = £5.49; 1 Unilet General Purpose Superlite c 100 Insuman c Comb 50 (Sanofi-Aventis) A = £3.67, 200 = £6.96; Unistik 3 Comfort c , 28-gauge, 100 = Injection, biphasic isophane insulin (human, crb), £6.24, 200 = £12.20; Unistik 3 Extra c , 21-gauge, 100 = £6.24, 50% soluble, 50% isophane, 100 units/mL, net price 5 200 = £12.20; Unistik 3 Normal c , 23-gauge, 100 = £6.24, Â 3-mL cartridge (for ClikSTAR c and OptiPen c Pro 200 = £12.20; Universal c (formerly VitalCare c ), 200 = 1) = £17.50; 5 Â 3-mL Insuman c Comb 50 OptiSet c £6.37; Vitrex Soft c , 23-gauge, 100 = £3.00, 200 = £5.70; Vitrex Gentle c 28-gauge, 100 = £3.19, 200 = £6.13; prefilled disposable injection devices (range 2– WaveSense Ultra-Thin c , 28-gauge, 200 = £6.90, 33-gauge, 40 units, allowing 2-unit dosage adjustment) = £17.50 200 = £6.90 Compatible finger-pricking devices (unless indicated otherwise, see footnotes), all D: B-D Optimus c , Glucolet c , Monojector c , Penlet II c , Soft Touch c 1. D Autolet c and D Autolet Impression c are also 6.1.1.3 Hypodermic equipment compatible finger-pricking devices 2. Use D Softclix c finger-pricking device Patients should be advised on the safe disposal of Needles lancets, single-use syringes, and needles. Suitable Hypodermic Needle, Sterile single use (Drug Tariff) arrangements for the safe disposal of contaminated For use with reusable glass syringe, sizes 0.5 mm (25G), waste must be made before these products are pre- 0.45 mm (26G), 0.4 mm (27G). Net price 100-needle pack = scribed for patients who are carriers of infectious dis- £2.74 eases. Brands include Microlance c , Monoject c
  • BNF 61 6.1.2 Antidiabetic drugs 427Needles for Prefilled and Reusable Pen Injectors (Drug Exenatide and liraglutide, both given by subcutaneousTariff) injection, are also available for the treatment of type 2 Screw on, needle length 6.1 mm or less, net price 100-needle diabetes, see section 6.1.2.3. pack = £12.53; 6.2–9.9 mm, 100-needle pack = £8.89; 10 mm or more, 100-needle pack = £8.89 Brands include BD Micro-Fine c +, NovoFine c , NovoTwist c , Pregnancy and breast-feeding During pregnancy, Unifine c Pentips women with pre-existing diabetes can be treated with Snap on, needle length 6.1 mm or less, net price 100-needle metformin [unlicensed use], either alone or in combina- pack = £12.02; 6.2–9.9 mm, 100-needle pack = £8.52; 10 mm tion with insulin (section 6.1.1). Metformin can be or more, 100-needle pack = £8.52 continued, or glibenclamide resumed, during breast- Brands include Penfine c feeding for those with pre-existing diabetes. Women with gestational diabetes may be treated, with or with- Syringes out concomitant insulin (section 6.1.1), with gliben-Hypodermic Syringe (Drug Tariff) clamide from 11 weeks gestation (after organogenesis) Calibrated glass with Luer taper conical fitting, for use with [unlicensed use] or with metformin [unlicensed use]. U100 insulin. Net price 0.5 mL and 1 mL = £9.22 Women with gestational diabetes should discontinue Brands include Abcare c hypoglycaemic treatment after giving birth.Pre-Set U100 Insulin Syringe (Drug Tariff) Other oral hypoglycaemic drugs, exenatide, and liraglu- Calibrated glass with Luer taper conical fitting, supplied with tide are contra-indicated in pregnancy. dosage chart and strong box, for blind patients. Net price 1 mL = £21.99 6.1.2.1 SulfonylureasU100 Insulin Syringe with Needle (Drug Tariff) Disposable with fixed or separate needle for single use or single patient-use, colour coded orange. Needle length 8 mm, The sulfonylureas act mainly by augmenting insulin diameters 0.33 mm (29G), 0.3 mm (30G), net price 10 (with secretion and consequently are effective only when needle), 0.3 mL = £1.38, 0.5 mL = £1.33, 1 mL = £1.32; needle some residual pancreatic beta-cell activity is present; length 12 mm, diameters 0.45 mm (26G), 0.4 mm (27G), during long-term administration they also have an 0.36 mm (28G), 0.33 mm (29G), net price 10 (with needle), 0.3 mL = £1.45; 0.5 mL = £1.43; 1 mL = £1.44 extrapancreatic action. All may cause hypoglycaemia Brands include BD Micro-Fine c +, Clinipak c , Insupak c , Mono- but this is uncommon and usually indicates excessive ject c Ultra, Omnikan c , Plastipak c dosage. Sulfonylurea-induced hypoglycaemia may per- sist for many hours and must always be treated in Accessories hospital.Needle Clipping (Chopping) Device (Drug Tariff) Sulfonylureas are considered for patients who are not Consisting of a clipper to remove needle from its hub and overweight, or in whom metformin is contra-indicated 6 Endocrine system container from which cut-off needles cannot be retrieved; designed to hold 1500 needles, not suitable for use with or not tolerated. Several sulfonylureas are available and lancets. Net price = £1.35 choice is determined by side-effects and the duration of Brands include BD Safe-Clip c action as well as the patient’s age and renal function. Glibenclamide, a long-acting sulfonylurea, is associatedSharpsguard (Drug Tariff) with a greater risk of hypoglycaemia; for this reason it Net price 1-litre sharpsbin = 85p should be avoided in the elderly, and shorter-acting alternatives, such as gliclazide or tolbutamide, should be used instead. When the combination of strict diet and sulfonylurea 6.1.2 Antidiabetic drugs treatment fails, other options include: 6.1.2.1 Sulfonylureas . combining with metformin (section 6.1.2.2) (reports 6.1.2.2 Biguanides of increased hazard with this combination remain unconfirmed); 6.1.2.3 Other antidiabetic drugs . combining with pioglitazone, but see section 6.1.2.3;Oral antidiabetic drugs are used for the treatment oftype 2 diabetes mellitus. They should be prescribed only . combining with saxagliptin, sitagliptin, or vildaglip-if the patient fails to respond adequately to at least 3 tin (section 6.1.2.3);months’ restriction of energy and carbohydrate intake . combining with exenatide or liraglutide (sectionand an increase in physical activity. They should be used 6.1.2.3);to augment the effect of diet and exercise, and not to . combining with acarbose (section 6.1.2.3), whichreplace them. may have a small beneficial effect, but flatulenceFor patients not adequately controlled by diet and oral can be a problem;hypoglycaemic drugs, insulin may be added to the . combining with bedtime isophane insulin (sectiontreatment regimen or substituted for oral therapy. 6.1.1) but weight gain and hypoglycaemia canWhen insulin is added to oral therapy, it is generally occur.given at bedtime as isophane or long-acting insulin, andwhen insulin replaces an oral regimen it may be given as The risk of hypoglycaemia associated with sulfonylureastwice-daily injections of a biphasic insulin (or isophane (see notes above) should be discussed with the patient,insulin mixed with soluble insulin), or a multiple injec- especially when concomitant glucose-lowering drugstion regimen. Weight gain and hypoglycaemia may be are prescribed.complications of insulin therapy but weight gain may be Insulin therapy should be instituted temporarily duringreduced if the insulin is given in combination with met- intercurrent illness (such as myocardial infarction,formin. coma, infection, and trauma). Sulfonylureas should be
  • 428 6.1.2 Antidiabetic drugs BNF 61 omitted on the morning of surgery; insulin is required Renal impairment see notes above because of the ensuing hyperglycaemia in these circum- Pregnancy see notes above stances. Breast-feeding see notes above Side-effects see notes above Cautions Sulfonylureas can encourage weight gain and should be prescribed only if poor control and Dose symptoms persist despite adequate attempts at dieting; . Initially 5 mg daily with or immediately after break- metformin (section 6.1.2.2) is considered the drug of fast, dose adjusted according to response (ELDERLY choice in obese patients. Caution is needed in the avoid, see notes above); max. 15 mg daily elderly. Glibenclamide (Non-proprietary) A Contra-indications Sulfonylureas should be avoided Tablets, glibenclamide 2.5 mg, net price 28-tab pack where possible in acute porphyria (section 9.8.2). Sulfo- = 95p; 5 mg, 28-tab pack = £1.07 nylureas are contra-indicated in the presence of keto- acidosis. GLICLAZIDE Hepatic impairment Sulfonylureas should be avoided or a reduced dose should be used in severe hepatic Indications type 2 diabetes mellitus impairment, because there is an increased risk of hypo- Cautions see notes above; interactions: Appendix 1 glycaemia. Jaundice may occur. (antidiabetics) Contra-indications see notes above Renal impairment Sulfonylureas should be used with Hepatic impairment see notes above care in those with mild to moderate renal impairment, Renal impairment see notes above because of the hazard of hypoglycaemia; they should be Pregnancy see notes above avoided where possible in severe renal impairment. Breast-feeding see notes above Glipizide should also be avoided if the patient has6 Endocrine system both renal and hepatic impairment. If necessary, the Side-effects see notes above short-acting drug tolbutamide can be used in renal Dose impairment, as can gliclazide which is principally meta- . Initially, 40–80 mg daily, adjusted according to bolised in the liver, but careful monitoring of blood- response; up to 160 mg as a single dose, with break- glucose concentration is essential; care is required to fast; higher doses divided; max. 320 mg daily use the lowest dose that adequately controls blood Gliclazide (Non-proprietary) A glucose. Tablets, scored, gliclazide 80 mg, net price 28-tab Pregnancy The use of sulfonylureas in pregnancy pack = £1.10, 60-tab pack = £1.52 Brands include DIAGLYK c should generally be avoided because of the risk of neo- natal hypoglycaemia; however, glibenclamide can be Diamicron c (Servier) A used during the second and third trimesters of Tablets, scored, gliclazide 80 mg, net price 60-tab pregnancy in women with gestational diabetes, see pack = £4.38 section 6.1.2. Modified release Breast-feeding The use of sulfonylureas (except glibenclamide [unlicensed use], see section 6.1.2) in Diamicron c MR (Servier) A breast-feeding should be avoided because there is a Tablets, m/r, gliclazide 30 mg, net price 28-tab pack = theoretical possibility of hypoglycaemia in the infant. £2.81, 56-tab pack = £5.62. Label: 25 Dose initially 30 mg daily with breakfast, adjusted according to response every 4 weeks (after 2 weeks if no decrease in blood Side-effects Side-effects of sulfonylureas are gener- glucose); max. 120 mg daily ally mild and infrequent and include gastro-intestinal Note Diamicron c MR 30 mg may be considered to be disturbances such as nausea, vomiting, diarrhoea, and approximately equivalent in therapeutic effect to standard constipation. Hyponatraemia has been reported with formulation Diamicron c 80 mg glimepiride and glipizide. Sulfonylureas can occasionally cause a disturbance in liver function, which may rarely lead to cholestatic GLIMEPIRIDE jaundice, hepatitis, and hepatic failure. Hypersensitivity Indications type 2 diabetes mellitus reactions can occur, usually in the first 6–8 weeks of Cautions see notes above; manufacturer recommends therapy. They consist mainly of allergic skin reactions regular hepatic and haematological monitoring but which progress rarely to erythema multiforme and limited evidence of clinical value; interactions: exfoliative dermatitis, fever, and jaundice; photosensit- Appendix 1 (antidiabetics) ivity has rarely been reported with glipizide. Blood disorders are also rare but may include leucopenia, Contra-indications see notes above thrombocytopenia, agranulocytosis, pancytopenia, Hepatic impairment see notes above haemolytic anaemia, and aplastic anaemia. Renal impairment see notes above Pregnancy see notes above Breast-feeding see notes above GLIBENCLAMIDE Side-effects see notes above Indications type 2 diabetes mellitus Dose Cautions see notes above; interactions: Appendix 1 . Initially 1 mg daily, adjusted according to response in (antidiabetics) 1-mg steps at 1–2 week intervals; usual max. 4 mg Contra-indications see notes above daily (exceptionally, up to 6 mg daily may be used); Hepatic impairment see notes above taken shortly before or with first main meal
  • BNF 61 6.1.2 Antidiabetic drugs 429Glimepiride (Non-proprietary) A there are some residual functioning pancreatic islet Tablets, glimepiride 1 mg, net price 30-tab pack = cells. £1.40; 2 mg, 30-tab pack = £1.38; 3 mg, 30-tab pack = Metformin is the drug of first choice in overweight £4.57; 4 mg, 30-tab pack = £1.75 patients in whom strict dieting has failed to controlAmaryl c (Sanofi-Aventis) A diabetes, if appropriate it may also be considered as Tablets, all scored, glimepiride 1 mg (pink), net price an option in patients who are not overweight. It is also 30-tab pack = £4.33; 2 mg (green), 30-tab pack = used when diabetes is inadequately controlled with £7.13; 3 mg (yellow), 30-tab pack = £10.75; 4 mg sulfonylurea treatment. When the combination of strict (blue), 30-tab pack = £14.24 diet and metformin treatment fails, other options include: . combining with a sulfonylurea (section 6.1.2.1) GLIPIZIDE (reports of increased hazard with this combination remain unconfirmed);Indications type 2 diabetes mellitus . combining with pioglitazone (section 6.1.2.3);Cautions see notes above; interactions: Appendix 1 (antidiabetics) . combining with repaglinide or nateglinide (section 6.1.2.3);Contra-indications see notes aboveHepatic impairment see notes above . combining with saxagliptin, sitagliptin, or vildaglip- tin (section 6.1.2.3);Renal impairment see notes abovePregnancy see notes above . combining with exenatide or liraglutide (sectionBreast-feeding see notes above 6.1.2.3);Side-effects see notes above; also dizziness, drowsi- . combining with acarbose (section 6.1.2.3), which ness may have a small beneficial effect, but flatulenceDose can be a problem;. Initially 2.5–5 mg daily shortly before breakfast or . combining with insulin (section 6.1.1) but weight lunch, adjusted according to response; max. 20 mg gain and hypoglycaemia can be problems (weight daily; up to 15 mg may be given as a single dose; gain minimised if insulin given at night). higher doses divided Insulin treatment is almost always required in medicalGlipizide (Non-proprietary) A and surgical emergencies; insulin should also be sub- Tablets, glipizide 5 mg, net price 56-tab pack = £4.23 stituted before elective surgery (omit metformin on the morning of surgery and give insulin if required).Minodiab c (Pharmacia) A Tablets, scored, glipizide 5 mg, net price 28-tab pack Hypoglycaemia does not usually occur with metformin; 6 Endocrine system = £1.26 other advantages are the lower incidence of weight gain and lower plasma-insulin concentration. It does not exert a hypoglycaemic action in non-diabetic subjects unless given in overdose. TOLBUTAMIDE Gastro-intestinal side-effects are initially common withIndications type 2 diabetes mellitus metformin, and may persist in some patients, particu-Cautions see notes above; interactions: Appendix 1 larly when very high doses such as 3 g daily are given. (antidiabetics) Very rarely, metformin can provoke lactic acidosis. It isContra-indications see notes above most likely to occur in patients with renal impairment,Hepatic impairment see notes above see Lactic Acidosis below.Renal impairment see notes above Metformin is used for the symptomatic management ofPregnancy see notes above polycystic ovary syndrome [unlicensed indication];Breast-feeding see notes above however, treatment should be initiated by a specialist.Side-effects see notes above; also headache, tinnitus Metformin improves insulin sensitivity, may aid weightDose reduction, helps to normalise menstrual cycle (increas- ing the rate of spontaneous ovulation), and may. 0.5–1.5 g (max. 2 g) daily in divided doses with or improve hirsutism. immediately after meals or as a single dose with or immediately after breakfastTolbutamide (Non-proprietary) A METFORMIN HYDROCHLORIDE Tablets, tolbutamide 500 mg, net price 28-tab pack = £1.74 Indications diabetes mellitus (see notes above); poly- cystic ovary syndrome [unlicensed indication] Cautions see notes above; determine renal function before treatment and at least annually (at least twice a year in patients with additional risk factors for renal 6.1.2.2 Biguanides impairment, or if deterioration suspected); interac- tions: Appendix 1 (antidiabetics)Metformin, the only available biguanide, has a different Lactic acidosis Use with caution in renal impairment—mode of action from the sulfonylureas, and is not inter- increased risk of lactic acidosis; avoid in significant renal impairment. NICE1 recommends that the dose should bechangeable with them. It exerts its effect mainly by reviewed if eGFR less than 45 mL/minute/1.73 m2 and todecreasing gluconeogenesis and by increasing periph-eral utilisation of glucose; since it acts only in the 1. NICE clinical guideline 87 (May 2009): Type 2 diabetes:presence of endogenous insulin it is effective only if The management of type 2 diabetes
  • 430 6.1.2 Antidiabetic drugs BNF 61 avoid if eGFR less than 30 mL/minute/1.73 m2 . Withdraw or 1 g twice daily with meals, and if control still not achieved change interrupt treatment in those at risk of tissue hypoxia or to standard-release tablets sudden deterioration in renal function, such as those with Note Patients taking up to 2 g daily of the standard-release met- dehydration, severe infection, shock, sepsis, acute heart formin may start with the same daily dose of metformin modified failure, respiratory failure or hepatic impairment, or those release; not suitable if dose of standard-release tablets more than who have recently had a myocardial infarction 2 g daily Contra-indications ketoacidosis, see also Lactic Aci- Brands include Bolamyn c SR, Metabet c SR dosis above; use of general anaesthesia (suspend Glucophage c SR (Merck Serono) A metformin on the morning of surgery and restart Tablets, m/r, metformin hydrochloride 500 mg, net when renal function returns to baseline) price 28-tab pack = £3.07, 56-tab pack = £6.14; Iodine-containing X-ray contrast media Intravascular 750 mg, 28-tab pack = £3.20, 56-tab pack = £6.40; 1 g, administration of iodinated contrast agents can cause renal failure. Suspend metformin prior to the test; restart at least 28-tab pack = £4.26, 56-tab pack = £8.52. Label: 21, 48 hours after the test if renal function has returned to 25 baseline Dose initially 500 mg once daily, increased every 10–15 days, Hepatic impairment withdraw if tissue hypoxia likely max. 2 g once daily with evening meal; if control not achieved, use 1 g twice daily with meals, and if control still not achieved change Renal impairment see under Cautions to standard-release tablets Pregnancy used in pregnancy for both pre-existing Note Patients taking up to 2 g daily of the standard-release met- and gestational diabetes—see also p. 427 formin may start with the same daily dose of Glucophage c SR; not suitable if dose of standard-release tablets more than 2 g daily Breast-feeding may be used during breast-feeding— The Scottish Medicines Consortium (p. 4) has advised (September see p. 427 2009) that Glucophage c SR is accepted for restricted use within Side-effects anorexia, nausea, vomiting, diarrhoea NHS Scotland for the treatment of type 2 diabetes mellitus in adult (usually transient), abdominal pain, taste disturbance, patients who are intolerant of standard-release metformin, and in whom the prolonged-release tablet allows the use of a dose of rarely lactic acidosis (withdraw treatment), decreased metformin not previously tolerated, or in patients for whom a vitamin-B12 absorption, erythema, pruritus and urti- once daily preparation offers a clinically significant benefit. caria; hepatitis also reported6 Endocrine system Dose With pioglitazone . Diabetes mellitus, ADULT and CHILD over 10 years Section 6.1.2.3 initially 500 mg with breakfast for at least 1 week then 500 mg with breakfast and evening meal for at least 1 With sitagliptin week then 500 mg with breakfast, lunch and evening Section 6.1.2.3 meal; usual max. 2 g daily in divided doses . Polycystic ovary syndrome [unlicensed], initially With vildagliptin 500 mg with breakfast for 1 week, then 500 mg with Section 6.1.2.3 breakfast and evening meal for 1 week, then 1.5–1.7 g daily in 2–3 divided doses Note Metformin doses in the BNF may differ from those in the 6.1.2.3 Other antidiabetic drugs product literature Metformin (Non-proprietary) A Acarbose, an inhibitor of intestinal alpha glucosidases, Tablets, coated, metformin hydrochloride 500 mg, net delays the digestion and absorption of starch and suc- price 28-tab pack = £1.07, 84-tab pack = £1.57; rose; it has a small but significant effect in lowering 850 mg, 56-tab pack = £1.67. Label: 21 blood glucose. Use of acarbose is usually reserved for Oral solution, sugar-free, metformin hydrochloride when other oral hypoglycaemics are not tolerated or are 500 mg/5 mL, net price 100 mL = £62.48. Label: 21 contra-indicated. Postprandial hyperglycaemia in type 1 Brands include Metsol c diabetes can be reduced by acarbose, but it has been little used for this purpose. Flatulence deters some from Glucophage c (Merck Serono) A using acarbose although this side-effect tends to Tablets, f /c, metformin hydrochloride 500 mg, net decrease with time. price 84-tab pack = £2.88; 850 mg, 56-tab pack = Nateglinide and repaglinide stimulate insulin release. £3.20. Label: 21 Both drugs have a rapid onset of action and short Oral powder, sugar-free, metformin hydrochloride duration of activity, and should be administered shortly 500 mg/sachet, net price 30-sachet pack = £3.29, 60- before each main meal. Repaglinide may be given as sachet pack = £6.58; 1 g/sachet, 30-sachet pack = monotherapy for patients who are not overweight or for £6.58, 60-sachet pack = £13.16. Label: 13, 21, coun- those in whom metformin is contra-indicated or not selling, administration tolerated, or it may be given in combination with met- Excipients include aspartame (section 9.4.1) Counselling The contents of each sachet should be mixed with formin. Nateglinide is licensed only for use with met- 150 mL of water and taken immediately formin. The Scottish Medicines Consortium (p. 4) has advised (March The thiazolidinedione, pioglitazone, reduces peripheral 2010) that Glucophage c oral powder is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes insulin resistance, leading to a reduction of blood-glu- mellitus in patients who are unable to swallow the solid dosage cose concentration. Pioglitazone can be used alone or in form. combination with metformin or with a sulfonylurea (if metformin inappropriate), or with both; the combination Modified release of pioglitazone plus metformin is preferred to pioglita- Metformin (Non-Proprietary) zone plus sulfonylurea, particularly for obese patients. Tablets, m/r, metformin hydrochloride 500 mg, net Inadequate response to a combination of metformin and price 28 tab-pack = £3.07, 56 tab-pack = £6.14. sulfonylurea may indicate failing insulin release; the Label: 21, 25 introduction of pioglitazone has a limited role in these Dose initially 500 mg once daily, increased every 10–15 days, circumstances and the initiation of insulin is often more max. 2 g once daily with evening meal; if control not achieved, use appropriate. Pioglitazone is also licensed in combination
  • BNF 61 6.1.2 Antidiabetic drugs 431with insulin, in patients who have not achieved ade- bination of sitagliptin and insulin (with or without met-quate glycaemic control with insulin alone, when met- formin) is also licensed for use when a stable dose offormin is inappropriate. Blood-glucose control may insulin has not provided adequate glycaemic control.deteriorate temporarily when pioglitazone is substituted NICE (May 2009) has recommended that, when glycae-for an oral antidiabetic drug that is being used in mic control is inadequate with existing treatment:combination with another. Long-term benefits of piogli-tazone have not yet been demonstrated. NICE (May . sitagliptin or vildagliptin (instead of a sulfonylurea)2009) has recommended that, when glycaemic control can be added to metformin, if there is a significantis inadequate with existing treatment, pioglitazone can risk of hypoglycaemia or if a sulfonylurea is contra-be added to: indicated or not tolerated;. a sulfonylurea, if metformin is contra-indicated or . sitagliptin or vildagliptin can be added to a sulfo- not tolerated; nylurea, if metformin is contra-indicated or not tolerated;. metformin, if risks of hypoglycaemia with sulfony- lurea are unacceptable or a sulfonylurea is contra- . sitagliptin can be added to both metformin and a indicated or not tolerated; sulfonylurea, if insulin is unacceptable because of lifestyle or other personal issues, or because the. a combination of metformin and a sulfonylurea, if patient is obese. insulin is unacceptable because of lifestyle or other personal issues, or because the patient is obese. NICE has recommended that treatment with sitagliptinNICE has recommended that treatment with pioglita- or vildagliptin is continued only if HbA1c concentrationzone is continued only if HbA1c concentration is reduced is reduced by at least 0.5% within 6 months of startingby at least 0.5% within 6 months of starting treatment. treatment.The Scottish Medicines Consortium (p. 4) accepts use of The Scottish Medicines Consortium (p. 4) has advisedpioglitazone (February 2007) with metformin and a that vildagliptin (Galvus c ) is accepted for restricted usesulfonylurea, for patients (especially if overweight) within NHS Scotland for the treatment of type 2whose glycaemic control is inadequate despite the use diabetes mellitus in combination with metformin whenof 2 oral hypoglycaemic drugs and who are unable or addition of a sulfonylurea is inappropriate (March 2008),unwilling to take insulin; treatment should be initiated and also in combination with a sulfonylurea if metforminand monitored by an experienced diabetes physician. is inappropriate (September 2009). Exenatide and liraglutide both bind to, and activate, MHRA/CHM advice the GLP-1 (glucagon-like peptide-1) receptor to increase Pioglitazone cardiovascular safety insulin secretion, suppress glucagon secretion, and slow (December 2007 and January 2011) gastric emptying. Treatment with exenatide and liraglu- tide is associated with the prevention of weight gain and 6 Endocrine system Incidence of heart failure is increased when piogli- tazone is combined with insulin especially in possible promotion of weight loss which can be bene- patients with predisposing factors e.g. previous myo- ficial in overweight patients. They are both given by cardial infarction. Patients who take pioglitazone subcutaneous injection for the treatment of type 2 dia- should be closely monitored for signs of heart fail- betes mellitus. ure; treatment should be discontinued if any dete- Exenatide is licensed in combination with metformin or rioration in cardiac status occurs. a sulfonylurea, or both, or with pioglitazone, or with Pioglitazone should not be used in patients with both metformin and pioglitazone, in patients who have heart failure or a history of heart failure. not achieved adequate glycaemic control with these drugs alone or in combination. Rosiglitazone NICE (May 2009) has recommended that, when glycae- The marketing authorisation for rosiglitazone mic control is inadequate with metformin and sulfony- (Avandia c , Avandamet c ) has been suspended lurea treatment, the addition of exenatide may be con- (September 2010) following a review by the sidered if the patient has: European Medicines Agency. The European Medi- . a body mass index of 35 kg/m2 or over and is of cines Agency concluded that the benefits of European descent (with appropriate adjustment for rosiglitazone treatment do not outweigh the cardi- other ethnic groups) and weight-related psycholo- ovascular risks. Prescribers should not issue new or gical or medical problems or repeat prescriptions for rosiglitazone. Treatment of . a body mass index less than 35 kg/m2 , and insulin patients who are taking rosiglitazone should be would be unacceptable for occupational reasons or reviewed. weight loss would benefit other significant obesity- related comorbidities.Saxagliptin, sitagliptin, and vildagliptin inhibit dipep-tidylpeptidase-4 to increase insulin secretion and lower NICE has recommended that treatment with exenatideglucagon secretion. They are licensed for use in type 2 is continued only if HbA1c concentration is reduced by atdiabetes in combination with metformin or a sulfonylur- least 1% and a weight loss of at least 3% is achievedea (if metformin inappropriate) or pioglitazone, when within 6 months of starting treatment.treatment with either metformin or a sulfonylurea or The Scottish Medicines Consortium (p. 4) has advisedpioglitazone fails to achieve adequate glycaemic con- (June 2007) that exenatide (Byetta c ) is accepted fortrol. Sitagliptin is also licensed for use as monotherapy restricted use within NHS Scotland for the treatment of(if metformin inappropriate), or in combination with type 2 diabetes in combination with metformin orboth metformin and a sulfonylurea, or both metformin sulfonylurea (or both), as an alternative to treatmentand pioglitazone when dual therapy with these drugs with insulin in patients where treatment with metforminfails to achieve adequate glycaemic control. The com- or sulfonylurea (or both) at maximally tolerated doses
  • 432 6.1.2 Antidiabetic drugs BNF 61 has been inadequate, and treatment with insulin would tention and pain; rarely, nausea, abnormal liver be the next option. function tests and skin reactions; very rarely ileus, Liraglutide is licensed for the treatment of type 2 dia- oedema, jaundice, and hepatitis Note Antacids unlikely to be beneficial for treating side- betes mellitus in combination with metformin or a effects sulfonylurea, or both, in patients who have not achieved adequate glycaemic control with these drugs alone or in Dose combination. Liraglutide is also licensed for use in . ADULT over 18 years, initially 50 mg daily increased to combination with both metformin and pioglitazone 50 mg 3 times daily, then increased if necessary after when dual therapy with these drugs fails to achieve 6–8 weeks to 100 mg 3 times daily; max. 200 mg 3 adequate glycaemic control. times daily Counselling Tablets should be chewed with first mouthful of food or swallowed whole with a little liquid immediately NICE guidance before food. To counteract possible hypoglycaemia, patients Liraglutide for the treatment of type 2 receiving insulin or a sulfonylurea as well as acarbose need to carry glucose (not sucrose—acarbose interferes with diabetes mellitus (October 2010) sucrose absorption) Liraglutide in triple therapy regimens (in combina- tion with metformin and a sulfonylurea, or met- Glucobay c (Bayer Schering) A formin and a thiazolidinedione) is recommended Tablets, acarbose 50 mg, net price 90-tab pack = for the treatment of type 2 diabetes, only when £6.15; 100 mg (scored), 90-tab pack = £11.35. Coun- glycaemic control is inadequate, and the patient has: selling, administration . a body mass index of 35 kg/m2 or over and is of European descent (with appropriate adjustment for other ethnic groups) and weight-related psy- chological or medical problems, or . a body mass index of less than 35 kg/m2 , and EXENATIDE6 Endocrine system insulin would be unacceptable for occupational Indications see notes above reasons or weight loss would benefit other sig- Cautions elderly; pancreatitis (see below); interac- nificant obesity-related comorbidities. tions: Appendix 1 (antidiabetics) Treatment with liraglutide in a triple therapy regi- Pancreatitis Severe pancreatitis (sometimes fatal), includ- men should be continued only if HbA1c concentra- ing haemorrhagic or necrotising pancreatitis, has been tion is reduced by at least 1% and a weight loss of at reported rarely. Patients or their carers should be told how to least 3% is achieved within 6 months of starting recognise signs and symptoms of pancreatitis and advised to seek prompt medical attention if symptoms such as abdo- treatment. minal pain, nausea, and vomiting develop; discontinue per- Liraglutide in dual therapy regimens (in combination manently if pancreatitis is diagnosed with metformin or a sulfonylurea) is recommended Contra-indications ketoacidosis; severe gastro-intes- only if: tinal disease . treatment with metformin or a sulfonylurea is Renal impairment use with caution if eGFR 30– contra-indicated or not tolerated, and 50 mL/minute/1.73 m2 ; avoid if eGFR less than . treatment with thiazolidinediones and dipepti- 30 mL/minute/1.73m2 dylpeptidase-4 inhibitors is contra-indicated or not tolerated. Pregnancy avoid—toxicity in animal studies Liraglutide, in combination with metformin or a Breast-feeding avoid—no information available sulfonylurea should be continued only if HbA1c con- Side-effects gastro-intestinal disturbances including centration is reduced by at least 1% within 6 months nausea, vomiting, diarrhoea, dyspepsia, abdominal of starting treatment. pain and distension, gastro-oesophageal reflux dis- Liraglutide 1.8 mg daily is not recommended. ease, decreased appetite; headache, dizziness, agita- tion, asthenia; hypoglycaemia; increased sweating, injection-site reactions; antibody formation; less commonly pancreatitis (see Cautions above); very rarely anaphylactic reactions; also reported consti- ACARBOSE pation, flatulence, eructation, dehydration, taste dis- Indications diabetes mellitus inadequately controlled turbance, renal impairment, drowsiness, rash, pru- by diet or by diet with oral antidiabetic drugs ritus, urticaria, and angioedema Cautions monitor liver function; may enhance hypo- Dose glycaemic effects of insulin and sulfonylureas (hypo- . By subcutaneous injection, ADULT over 18 years, glycaemic episodes may be treated with oral glucose initially 5 micrograms twice daily within 1 hour before but not with sucrose); interactions: Appendix 1 2 main meals (at least 6 hours apart), increased if (antidiabetics) necessary after at least 1 month to max. 10 micr- Contra-indications inflammatory bowel disease, pre- ograms twice daily Counselling If a dose is missed, continue with the next disposition to partial intestinal obstruction; hernia, scheduled dose—do not administer after a meal. Some oral previous abdominal surgery medications should be taken at least 1 hour before or 4 hours Hepatic impairment avoid after exenatide injection—consult product literature for details Renal impairment avoid if eGFR less than 25 mL/ minute/1.73 m2 Byetta c (Lilly) T A Pregnancy avoid Injection, exenatide 250 micrograms/mL, net price Breast-feeding avoid 5 microgram/dose prefilled pen (60 doses) = £68.24, Side-effects flatulence, soft stools, diarrhoea (may 10 microgram/dose prefilled pen (60 doses) = £68.24. need to reduce dose or withdraw), abdominal dis- Counselling, administration
  • BNF 61 6.1.2 Antidiabetic drugs 433 LIRAGLUTIDE PIOGLITAZONEIndications see notes above Indications type 2 diabetes mellitus (alone or com-Cautions discontinue if symptoms of acute pancreat- bined with metformin or a sulfonylurea, or with both, itis (persistent, severe abdominal pain); interactions: or with insulin—see also notes above) Appendix 1 (antidiabetics) Cautions monitor liver function (see below); cardio-Contra-indications ketoacidosis; inflammatory bowel vascular disease or in combination with insulin (risk of disease; diabetic gastroparesis heart failure—see MHRA/CHM advice p. 431); sub-Hepatic impairment avoid—limited experience stitute insulin during peri-operative period (omit pio- glitazone on morning of surgery and recommenceRenal impairment avoid if eGFR less than 60 mL/ when eating and drinking normally); increased risk of minute/1.73 m2 —limited experience bone fractures, particularly in women; avoid in acutePregnancy avoid—toxicity in animal studies porphyria (but see section 9.8.2); interactions:Breast-feeding avoid—no information available Appendix 1 (antidiabetics)Side-effects gastro-intestinal disturbances including Liver toxicity Rare reports of liver dysfunction; monitor nausea, vomiting, constipation, diarrhoea, dyspepsia, liver function before treatment, and periodically thereafter; abdominal pain and distension, flatulence, gastritis, advise patients to seek immediate medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue gastro-oesophageal reflux disease, decreased appe- and dark urine develop; discontinue if jaundice occurs tite; headache, dizziness, fatigue; fever, bronchitis, Contra-indications history of heart failure nasopharyngitis; hypoglycaemia; injection site reac- Hepatic impairment avoid; see also Cautions above tions; also reported acute pancreatitis, thyroid neo- plasm, goitre, increased blood calcitonin, angioedema Pregnancy avoid—toxicity in animal studies Breast-feeding avoid—present in milk in animalDose studies. By subcutaneous injection, ADULT over 18 years, initially 0.6 mg once daily, increased after at least 1 Side-effects gastro-intestinal disturbances, weight week to 1.2 mg once daily, further increased if gain, oedema, anaemia, headache, visual distur- necessary after an interval of at least 1 week to max. bances, dizziness, arthralgia, hypoaesthesia, haema- 1.8 mg once daily turia, impotence; less commonly hypoglycaemia, Note Dose of concomitant sulfonylurea may need to be fatigue, insomnia, vertigo, sweating, altered blood reduced lipids, proteinuria; see also Liver Toxicity above DoseVictoza c (Novo Nordisk) T A . ADULT over 18 years, initially 15–30 mg once daily Injection, liraglutide 6 mg/mL, net price 2 Â 3-mL increased to 45 mg once daily according to response prefilled pens = £78.48, 3 Â 3-mL prefilled pens = Note Dose of concomitant sulfonylurea or insulin may need £117.72. Counselling, administration to be reduced 6 Endocrine system Actos c (Takeda) T A Tablets, pioglitazone (as hydrochloride) 15 mg, net price 28-tab pack = £25.83; 30 mg, 28-tab pack = NATEGLINIDE £35.89; 45 mg, 28-tab pack = £39.55Indications type 2 diabetes mellitus in combination With metformin with metformin (section 6.1.2.2) when metformin alone inadequate For prescribing information on metformin, see section 6.1.2.2Cautions substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection, and Competact c (Takeda) T A trauma) and during surgery (omit nateglinide on Tablets, f/c, pioglitazone (as hydrochloride) 15 mg, morning of surgery and recommence when eating and metformin hydrochloride 850 mg, net price 56-tab drinking normally); elderly, debilitated and malnour- pack = £35.89. Label: 21 ished patients; interactions: Appendix 1 (anti- Dose ADULT over 18 years, type 2 diabetes not controlled by diabetics) metformin alone, 1 tablet twice dailyContra-indications ketoacidosis Note Titration with the individual components (pioglitazone and metformin) desirable before initiating Competact cHepatic impairment caution in moderate hepatic impairment; avoid in severe impairment—no infor- mation availablePregnancy avoid—toxicity in animal studies REPAGLINIDEBreast-feeding avoid—present in milk in animal Indications type 2 diabetes mellitus (as monotherapy studies or in combination with metformin when metforminSide-effects hypoglycaemia; hypersensitivity reac- alone inadequate) tions including pruritus, rashes and urticaria Cautions substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection, andDose trauma) and during surgery (omit repaglinide on. ADULT over 18 years, initially 60 mg 3 times daily morning of surgery and recommence when eating and within 30 minutes before main meals, adjusted drinking normally); debilitated and malnourished according to response up to max. 180 mg 3 times daily patients; interactions: Appendix 1 (antidiabetics)Starlix c (Novartis) A Contra-indications ketoacidosis Tablets, f/c, nateglinide 60 mg (pink), net price 84-tab Hepatic impairment avoid in severe liver disease pack = £22.71; 120 mg (yellow), 84-tab pack = £25.88; Renal impairment use with caution 180 mg (red), 84-tab pack = £25.88 Pregnancy avoid
  • 434 6.1.2 Antidiabetic drugs BNF 61 Breast-feeding avoid—present in milk in animal Dose studies . ADULT over 18 years, 100 mg once daily Side-effects abdominal pain, diarrhoea, constipation, Note Dose of concomitant sulfonylurea or insulin may need to nausea, vomiting; rarely hypoglycaemia, hypersensi- be reduced tivity reactions including pruritus, rashes, vasculitis, urticaria, and visual disturbances Januvia c (MSD) T A Tablets, beige, f/c, sitagliptin (as phosphate) 100 mg, Dose net price 28-tab pack = £33.26 . ADULT over 18 years, initially 500 micrograms within The Scottish Medicines Consortium (p. 4) has advised (June 2010) 30 minutes before main meals (1 mg if transferring that Januvia c is accepted for restricted use within NHS Scotland from another oral hypoglycaemic), adjusted according as monotherapy, to improve glycaemic control in patients with to response at intervals of 1–2 weeks; up to 4 mg may type 2 diabetes mellitus, for whom both metformin and sulfonylureas are not appropriate be given as a single dose, max. 16 mg daily; ELDERLY over 75 years, not recommended With metformin Prandin c (Daiichi Sankyo) A For prescribing information on metformin, see section Tablets, repaglinide 500 micrograms, net price 30-tab 6.1.2.2 pack = £3.92, 90-tab pack = £11.76; 1 mg (yellow), 30- tab pack = £3.92, 90-tab pack = £11.76; 2 mg (peach), Janumet c (MSD) T A 90-tab pack = £11.76 Tablets, f/c, red, sitagliptin 50 mg, metformin hydro- Formerly marketed as NovoNorm c chloride 1 g, net price 56-tab pack = £34.56. Label: 21 Dose type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or pioglitazone or insulin, ADULT over 18 years, 1 tablet twice daily SAXAGLIPTIN Note Dose of concomitant sulfonylurea or insulin may need to be Indications see notes above reduced6 Endocrine system The Scottish Medicines Consortium (p. 4) has advised (July 2008) Cautions elderly; interactions: Appendix 1 (anti- that Janumet c is accepted for restricted use within NHS Scotland diabetics) for the treatment of type 2 diabetes mellitus when the addition of a Hepatic impairment use with caution in moderate sulfonylurea to metformin is not appropriate; it is also accepted for use in NHS Scotland in combination with a sulfonylurea in impairment; avoid in severe impairment patients inadequately controlled on maximum tolerated doses of Renal impairment avoid if eGFR less than 50 mL/ metformin and a sulfonylurea. minute/1.73m2 Pregnancy avoid unless essential—toxicity in animal studies Breast-feeding avoid—present in milk in animal VILDAGLIPTIN studies Indications type 2 diabetes mellitus (in combination Side-effects vomiting, dyspepsia, gastritis; peripheral with metformin or with a sulfonylurea or with piogli- oedema; headache, dizziness, fatigue; upper respir- tazone—see also notes above) atory tract infection, urinary tract infection, gastro- enteritis, sinusitis, nasopharyngitis; hypoglycaemia, Cautions elderly; monitor liver function (see below); myalgia; less commonly dyslipidaemia, hypertrigly- heart failure (avoid if moderate or severe); interac- ceridaemia, erectile dysfunction, arthralgia; also tions: Appendix 1 (antidiabetics) Liver toxicity Rare reports of liver dysfunction; monitor reported rash liver function before treatment and every 3 months for first Dose year and periodically thereafter; advise patients to seek . ADULT over 18 years, 5 mg once daily prompt medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue, and dark urine develop; Note Dose of concomitant sulfonylurea may need to be discontinue if jaundice or other signs of liver dysfunction reduced occur Onglyza c (Bristol-Myers Squibb) T A Contra-indications ketoacidosis Tablets, pink, f/c, saxagliptin (as hydrochloride) 5 mg, Hepatic impairment avoid; see also Cautions above net price 28-tab pack = £31.60 Renal impairment avoid if eGFR less than 50 mL/ minute/1.73 m2 Pregnancy avoid—toxicity in animal studies SITAGLIPTIN Breast-feeding avoid—present in milk in animal studies Indications see notes above Side-effects nausea, peripheral oedema, headache, Cautions interactions: Appendix 1 (antidiabetics) tremor, asthenia, dizziness; less commonly constipa- Contra-indications ketoacidosis tion, hypoglycaemia, arthralgia; rarely hepatic dys- Renal impairment avoid if eGFR less than 50 mL/ function (see also Liver Toxicity above); very rarely minute/1.73 m2 nasopharyngitis, upper respiratory tract infection; Pregnancy avoid—toxicity in animal studies pancreatitis also reported Breast-feeding avoid—present in milk in animal Dose studies . ADULT over 18 years, in combination with metformin or Side-effects gastro-intestinal disturbances; peripheral pioglitazone, 50 mg twice daily; in combination with a oedema; upper respiratory tract infection, nasophar- sulfonylurea, 50 mg daily in the morning yngitis; pain; less commonly dry mouth, anorexia, headache, drowsiness, dizziness, hypoglycaemia, Galvus c (Novartis) T A osteoarthritis; also reported pancreatitis, rash, cuta- Tablets, pale yellow, vildagliptin 50 mg, net price 56- neous vasculitis, and Stevens-Johnson syndrome tab pack = £31.76
  • BNF 61 6.1.3 Diabetic ketoacidosis 435 With metformin above 7.3 and the patient is able to eat and drink; For prescribing information on metformin, see section ideally give subcutaneous fast-acting insulin and a 6.1.2.2 meal, and stop the insulin infusion 1 hour later.Eucreas c (Novartis) T A For the management of diabetic ketoacidosis in children Eucreas c 50 mg/850 mg tablets, f/c, yellow, vilda- under 18 years, see BNF for Children. gliptin 50 mg, metformin hydrochloride 850 mg, net The management of hyperosmolar hyperglycaemic price 60-tab pack = £31.76. Label: 21 state or hyperosmolar hyperglycaemic nonketotic Eucreas c 50 mg/1 g tablets, f/c, dark yellow, coma is similar to that of diabetic ketoacidosis, although vildagliptin 50 mg, metformin hydrochloride 1 g, net lower rates of insulin infusion are usually necessary and price 60-tab pack = £31.76. Label: 21 slower rehydration may be required. Dose type 2 diabetes mellitus not controlled by metformin alone, ADULT over 18 years, 1 Eucreas c tablet twice daily (based on patient’s current metformin dose) The Scottish Medicines Consortium (p. 4) has advised (June 2008) that Eucreas c is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in patients unable to achieve adequate glycaemic control with metformin alone or those already treated with vildagliptin and metformin as separate tablets 6.1.4 Treatment of hypoglycaemia Initially glucose 10–20 g is given by mouth either in 6.1.3 Diabetic ketoacidosis liquid form or as granulated sugar or sugar lumps. Approximately 10 g of glucose is available from non-The management of diabetic ketoacidosis involves the diet versions of Lucozade c Energy Original 55 mL,replacement of fluid and electrolytes and the adminis- Coca-Cola c 100 mL, Ribena c Blackcurrant 18 mL (totration of insulin. Guidelines for the Management of be diluted), 2 teaspoons of sugar, and also from 3 sugarDiabetic Ketoacidosis in Adults, published by the Joint lumps2 . If necessary this may be repeated in 10–15British Diabetes Societies Inpatient Care Group1, should minutes. After initial treatment, a snack providingbe followed. sustained availability of carbohydrate (e.g. a sandwich,. To restore circulating volume if systolic blood pres- fruit, milk, or biscuits) or the next meal, if it is due, can sure is below 90 mmHg (adjusted for age, sex, and prevent blood-glucose concentration from falling again. medication as appropriate), give 500 mL sodium Hypoglycaemia which causes unconsciousness is an chloride 0.9% by intravenous infusion over 10–15 emergency. Glucagon, a polypeptide hormone pro- minutes; repeat if blood pressure remains below duced by the alpha cells of the islets of Langerhans, 6 Endocrine system 90 mmHg and seek senior medical advice. increases plasma-glucose concentration by mobilising. When blood pressure is over 90 mmHg, sodium glycogen stored in the liver. In hypoglycaemia, if sugar chloride 0.9% should be given by intravenous infu- cannot be given by mouth, glucagon can be given by sion at a rate that replaces deficit and provides injection. Carbohydrates should be given as soon as maintenance; see guideline for suggested regimen. possible to restore liver glycogen; glucagon is not appro-. Include potassium chloride in the fluids unless priate for chronic hypoglycaemia. Glucagon may be anuria is suspected; adjust according to plasma- issued to close relatives of insulin-treated patients for potassium concentration (measure at 60 minutes, emergency use in hypoglycaemic attacks. It is often 2 hours, and 2 hourly thereafter; measure hourly if advisable to prescribe on an ‘if necessary’ basis to outside the normal range). hospitalised insulin-treated patients, so that it may be. Start an intravenous insulin infusion: soluble insu- given rapidly by the nurses during an hypoglycaemic lin should be diluted (and mixed thoroughly) with emergency. If not effective in 10 minutes intravenous sodium chloride 0.9% intravenous infusion to a glucose should be given. concentration of 1 unit/mL; infuse at a fixed rate of Alternatively, 50 mL of glucose intravenous infusion 0.1 units/kg/hour. 20% (section 9.2.2) may be given intravenously into a. Established subcutaneous therapy with long-acting large vein through a large-gauge needle; care is required insulin analogues (insulin detemir or insulin glar- since this concentration is irritant especially if extrava- gine) should be continued during treatment of dia- sation occurs. Glucose intravenous infusion 10% may betic ketoacidosis. also be used but larger volumes are needed. Glucose. Monitor blood-ketone and blood-glucose concen- intravenous infusion 50% is not recommended because trations hourly and adjust the insulin infusion rate of the higher risk of extravasation injury and because accordingly. Blood-ketone concentration should fall administration is difficult. Close monitoring is necessary by at least 0.5 mmol/litre/hour and blood-glucose in the case of an overdose with a long-acting insulin concentration should fall by at least 3 mmol/litre/ because further administration of glucose may be hour. required. Patients whose hypoglycaemia is caused by an oral antidiabetic drug should be transferred to hos-. Once blood-glucose concentration falls below pital because the hypoglycaemic effects of these drugs 14 mmol/litre, glucose 10% should be given by may persist for many hours. intravenous infusion (into a large vein through a large-gauge needle) at a rate of 125 mL/hour, in For advice on the emergency management of hypoglyc- addition to the sodium chloride 0.9% infusion. aemia in dental practice, see p. 28.. Continue insulin infusion until blood-ketone con- 2. Proprietary products of quick-acting carbohydrate (e.g. centration is below 0.3 mmol/litre, blood pH is GlucoGel c , Dextrogel c , Hypo-Fit c ) are available on prescription for the patient to keep to hand in case of1. Available at www.diabetes.nhs.uk hypoglycaemia.
  • 436 6.1.5 Treatment of diabetic nephropathy and neuropathy BNF 61 GLUCAGON 6.1.5 Treatment of diabetic Indications see notes above and under Dose nephropathy and Cautions see notes above, insulinoma, glucagonoma; ineffective in chronic hypoglycaemia, starvation, and neuropathy adrenal insufficiency Contra-indications phaeochromocytoma Side-effects nausea, vomiting, abdominal pain, Diabetic nephropathy hypokalaemia, hypotension, rarely hypersensitivity Regular review of diabetic patients should include an reactions annual test for urinary protein (using Albustix c ) and Dose serum creatinine measurement. If the urinary protein . Insulin-induced hypoglycaemia, by subcutaneous, test is negative, the urine should be tested for intramuscular, or intravenous injection, ADULT and microalbuminuria (the earliest sign of nephropathy). If CHILD over 8 years (or body-weight over 25 kg), 1 mg; reagent strip tests (Micral-Test II c D or Micro- CHILD under 8 years (or body-weight under 25 kg), bumintest c D) are used and prove positive, the result 500 micrograms; if no response within 10 minutes should be confirmed by laboratory analysis of a urine intravenous glucose must be given sample. Provided there are no contra-indications, all . Diagnostic aid, consult product literature diabetic patients with nephropathy causing proteinuria . Beta-blocker poisoning, see p. 37 or with established microalbuminuria (at least 3 positive Note 1 unit of glucagon = 1 mg of glucagon tests) should be treated with an ACE inhibitor (section 2.5.5.1) or an angiotensin-II receptor antagonist (section 1 GlucaGen c HypoKit (Novo Nordisk) A 2.5.5.2) even if the blood pressure is normal; in any case, Injection, powder for reconstitution, glucagon (rys) as to minimise the risk of renal deterioration, blood hydrochloride with lactose, net price 1-mg vial with pressure should be carefully controlled (section 2.5). prefilled syringe containing water for injection =6 Endocrine system £11.52 ACE inhibitors can potentiate the hypoglycaemic effect 1. A restriction does not apply where administration is for of insulin and oral antidiabetic drugs; this effect is more saving life in emergency likely during the first weeks of combined treatment and in patients with renal impairment. For the treatment of hypertension in diabetes, see sec- tion 2.5. Chronic hypoglycaemia Diabetic neuropathy Diazoxide, administered by mouth, is useful in the Optimal diabetic control is beneficial for the manage- management of patients with chronic hypoglycaemia ment of painful neuropathy in patients with type 1 from excess endogenous insulin secretion, either from diabetes (see also section 4.7.3). Paracetamol (p. 259) an islet cell tumour or islet cell hyperplasia. It has no or a non-steroidal anti-inflammatory drug such as ibu- place in the management of acute hypoglycaemia. profen (p. 636) may relieve mild to moderate pain. Duloxetine (p. 243) is effective for the treatment of painful diabetic neuropathy; amitriptyline (p. 235) [unlicensed use] can be used if duloxetine is ineffective DIAZOXIDE or unsuitable. Nortriptyline (p. 236) [unlicensed] may Indications chronic intractable hypoglycaemia; be better tolerated than amitriptyline. If treatment with hypertensive emergency—but no longer recom- amitriptyline or duloxetine is inadequate, treatment with mended, see section 2.5 pregabalin (p. 284) should be tried. Combination ther- Cautions ischaemic heart disease; monitor blood apy of duloxetine or amitriptyline with pregabalin can be pressure; during prolonged use monitor white cell and used if monotherapy at the maximum tolerated dose platelet count, and in children, regularly assess does not control symptoms. growth, bone, and psychological development; inter- Neuropathic pain may respond to opioid analgesics. actions: Appendix 1 (diazoxide) There is evidence of efficacy for tramadol (p. 271), Renal impairment dose reduction may be required morphine (p. 268), and oxycodone (p. 269); however, Pregnancy prolonged use in second or third trimesters treatment with morphine or oxycodone should be may produce alopecia and impaired glucose tolerance initiated only under specialist supervision. Tramadol in neonate; inhibits uterine activity during labour can be prescribed while the patient is waiting for assess- Side-effects anorexia, nausea, vomiting, hyperuric- ment by a specialist if other treatments have been aemia, hypotension, oedema, tachycardia, arrhyth- unsuccessful. mias, extrapyramidal effects; hypertrichosis on pro- Gabapentin (p. 284) and carbamazepine (p. 281) are longed treatment sometimes used for the treatment of neuropathic pain. Dose Capsaicin cream 0.075% (p. 664) is licensed for painful . By mouth, ADULT and CHILD, initially 5 mg/kg daily in diabetic neuropathy and may have some effect, but it 2–3 divided doses produces an intense burning sensation during the initial treatment period. Eudemine c (UCB Pharma) A In autonomic neuropathy diabetic diarrhoea can often Tablets, diazoxide 50 mg. Net price 100 = £44.64 be managed by 2 or 3 doses of tetracycline 250 mg Injection, see section 2.5.1 [unlicensed use] (p. 347). Otherwise codeine (p. 58) is
  • BNF 61 6.1.6 Diagnostic and monitoring devices for diabetes mellitus 437the best drug, but other antidiarrhoeal preparations can If the patient is unwell and diabetic ketoacidosis isbe tried. An antiemetic which promotes gastric transit, suspected, blood ketones should be measured accord-such as metoclopramide (p. 253) or domperidone ing to local guidelines (section 6.1.3). Patients and their(p. 253), is helpful for gastroparesis. In rare cases carers should be trained in the use of blood ketonewhen an antiemetic does not help, erythromycin (espe- monitoring systems and to take appropriate action oncially when given intravenously) may be beneficial but the results obtained, including when to seek medicalthis needs confirmation. attention.In neuropathic postural hypotension increased saltintake and the use of the mineralocorticoid fludrocorti-sone 100–400 micrograms daily [unlicensed use](p. 442) may help by increasing plasma volume, butuncomfortable oedema is a common side-effect. Fludro- Urinalysiscortisone can also be combined with flurbiprofen Tests for glucose range from reagent strips specific to(p. 636) and ephedrine hydrochloride (p. 179) [both glucose to reagent tablets which detect all reducingunlicensed]. Midodrine [unlicensed], an alpha agonist, sugars. Few patients still use Clinitest c ; Clinistix c ismay also be useful in postural hypotension. suitable for screening purposes only. Tests for ketonesGustatory sweating can be treated with an anti- by patients are rarely required unless they becomemuscarinic such as propantheline bromide (p. 48); unwell—see also Blood Monitoring, above.side-effects are common. For the management of hyper- Microalbuminuria can be detected with Micral-Testhidrosis, see section 13.12. II c D but this should be followed by confirmation inIn some patients with neuropathic oedema, ephedrine the laboratory, since false positive results are common.hydrochloride [unlicensed use] 30–60 mg 3 times dailyoffers effective relief. Glucose Clinistix c (Bayer Diabetes Care)For the management of erectile dysfunction, see section Reagent strips, for detection of glucose in urine. Net price7.4.5. 50-strip pack = £3.27 Clinitest c (Bayer Diabetes Care) D Reagent tablets, for detection of glucose and other reducing 6.1.6 Diagnostic and substances in urine. Net price 36-tab pack = £2.00 monitoring devices for Diabur-Test 5000c (Roche Diagnostics) diabetes mellitus Reagent strips, for detection of glucose in urine. Net price 50-strip pack = £2.87 6 Endocrine system Diastix c (Bayer Diabetes Care)Blood monitoring Reagent strips, for detection of glucose in urine. Net price 50-strip pack = £2.78Blood glucose monitoring using a meter gives a directmeasure of the glucose concentration at the time of the Medi-Test c Glucose (BHR)test and can detect hypoglycaemia as well as hyperglyc- Reagent strips, for detection of glucose in urine. Net priceaemia. Patients should be properly trained in the use of 50-strip pack = £2.33blood glucose monitoring systems and to take appro-priate action on the results obtained. Inadequate under- Ketonesstanding of the normal fluctuations in blood glucose can Ketostixc (Bayer Diabetes Care)lead to confusion and inappropriate action. Reagent strips, for detection of ketones in urine. Net price 50-strip pack = £2.95Patients using multiple injection regimens should under-stand how to adjust their insulin dose according to their Ketur Test c (Roche Diagnostics)carbohydrate intake. With fixed-dose insulin regimens, Reagent strips, for detection of ketones in urine. Net pricethe carbohydrate intake needs to be regulated, and 50-strip pack = £2.76should be distributed throughout the day to match theinsulin regimen. Protein Albustix c (Siemens)Self-monitoring of blood-glucose concentration is Reagent strips, for detection of protein in urine. Net priceappropriate for patients with type 2 diabetes: 50-strip pack = £4.10. who are treated with insulin;. who are treated with oral hypoglycaemic drugs e.g. Medi-Test c Protein 2 (BHR) sulfonylureas, to provide information on hypoglyc- Reagent strips, for detection of protein in urine. Net price aemia; 50-strip pack = £3.27. to monitor changes in blood-glucose concentration Other reagent strips available for urinalysis resulting from changes in lifestyle or medication, include: and during intercurrent illness; Combur-3 Test c D (glucose and protein—Roche. to ensure safe blood-glucose concentration during Diagnostics), Clinitek Microalbumin c D (albumin and activities, including driving. creatinine—Siemens), Ketodiastix c D (glucose andNote In the UK blood-glucose concentration is expressed in ketones—Bayer Diagnostics), Medi-Test Combi 2 c Dmmol/litre and Diabetes UK advises that these units should be (glucose and protein—BHR), Micral-Test II c Dused for self-monitoring of blood glucose. In other Europeancountries units of mg/100 mL (or mg/dL) are commonly used. (albumin—Roche Diagnostics), Microalbustix c DIt is advisable to check that the meter is pre-set in the correct (albumin and creatinine—Siemens), Uristix c D (glu-units. cose and protein—Siemens)
  • 438 6.1.6 Diagnostic and monitoring devices for diabetes mellitus BNF 61 Meters and test strips Meter (all D) Type of Meter Compatible Test strip Sensitivity Manufacturer monitoring retail price test strips net price range (mmol/ litre) Accu-Chek c Active1 Blood glucose Active c 50-strip pack 0.6–33.3 Roche = £15.16 Diagnostics Accu-Chek c Blood glucose Advantage Plus c 50-strip pack 0.6–33.3 Roche Advantage1 = £15.17 Diagnostics Accu-Chek c Aviva Blood glucose £12.99 Aviva c 50-strip pack 0.6–33.3 Roche = £14.89 Diagnostics Accu-Chek c Blood glucose Compact c 3 Â 17-strip pack 0.6–33.3 Roche Compact1 = £15.29 Diagnostics Accu-Chek c Blood glucose £12.99 Compact c 3 Â 17-strip pack 0.6–33.3 Roche Compact Plus = £15.29 Diagnostics Accu-Chek c Mobile Blood glucose £49.99 Mobile c 100 tests = £30.12 0.3–33.3 Roche Diagnostics c1 Accutrend Blood glucose BM-Accutest c 50-strip pack 1.1–33.3 Roche = £14.31 Diagnostics Ascensia Breeze c 1 Blood glucose Ascensiac 5 Â 10-disc pack 0.6–33.3 Bayer Autodisc = £14.62 Diabetes Care6 Endocrine system Ascensia Esprit c 21 Blood glucose Ascensiac 5 Â 10-disc pack 0.6–33.3 Bayer Autodisc = £14.62 Diabetes Care Breeze 2 c Blood glucose £14.34 Breeze 2 c 5 Â 10-disc pack 0.6–33.3 Bayer = £14.34 Diabetes Care CareSens N c 2 Blood glucose CareSens N c 50-strip pack 1.1–33.3 Spirit = £12.75 Healthcare Contour c Blood glucose £10.80 Contour c 50-strip pack 0.6–33.3 Bayer Formerly Ascensia c = £14.74 Diabetes Microfill Care FreeStyle c 1 Blood glucose FreeStyle c 50-strip pack 1.1–27.8 Abbott = £14.90 FreeStyle Blood glucose FreeStyle c 50-strip pack 1.1–27.8 Abbott Freedom c 1 = £14.90 FreeStyle Freedom Blood glucose £11.49 FreeStyle Lite c 50-strip pack 1.1–27.8 Abbott Lite c = £14.90 FreeStyle Lite c Blood glucose £14.94 FreeStyle Lite c 50-strip pack 1.1–27.8 Abbott = £14.90 c1 FreeStyle Mini Blood glucose FreeStyle c 50-strip pack 1.1–27.8 Abbott = £14.90 GlucoMen c Glyco1 ´ Blood glucose GlucoMenc 50-strip pack 1.1–33.3 Menarini = £13.67 Diagnostics GlucoMen c GM Blood glucose £15.26 GlucoMen GM c 50-strip pack 0.6–33.3 Menarini = £14.67 Diagnostics GlucoMen c LX Blood glucose £14.94 GlucoMenc LX 50-strip pack 1.1–33.3 Menarini = £14.65 Diagnostics GlucoMen c PC1 Blood glucose GlucoMenc 50-strip pack 1.1–33.3 Menarini = £13.67 Diagnostics GlucoMen c Visio Blood glucose £10.34 GlucoMenc Visio 50-strip pack 1.1–33.3 Menarini Sensor = £14.53 Diagnostics Glucotrend c 1 Blood glucose Active c 50-strip pack 0.6–33.3 Roche = £14.76 Diagnostics One Touch c II1 Blood glucose One Touch c 50-strip pack 1.1–33.3 LifeScan = £14.59 One Touch c Basic1 Blood glucose One Touch c 50-strip pack 1.1–33.3 LifeScan = £14.59 1. Meter no longer available 2. Free of charge from diabetes healthcare professionals
  • BNF 61 6.2 Thyroid and antithyroid drugs 439 Meter (all D) Type of Meter Compatible Test strip Sensitivity Manufacturer monitoring retail price test strips net price range (mmol/ litre) One Touch c Profile1 Blood glucose One Touch c 50-strip pack 1.1–33.3 LifeScan = £14.59 One Touch Ultra c 1 Blood glucose One Touch Ultra c 50-strip pack 1.1–33.3 LifeScan = £14.75 One Touch Ultra 2 c Blood glucose £25.98 One Touch Ultra c 50-strip pack 1.1–33.3 LifeScan = £14.75 One Touch Blood glucose £25.98 One Touch Ultra c 50-strip pack 1.1–33.3 LifeScan UltraEasy c = £14.75 One Touch Blood glucose One Touch Ultra c 50-strip pack 1.1–33.3 LifeScan UltraSmart c 2 = £14.75 One Touch c Vita2 Blood glucose One Touch c Vita50-strip pack 1.1–33.3 LifeScan = £14.81 c1 Optium Blood ketones Optium b-ketone 10-strip pack c 0–8.0 Abbott = £19.92 Optium Xceed c Blood glucose £17.24 Optium 50-strip pack 1.1–27.8 Abbott Plus c Formerly Med- = £14.80 isense c Optium Plus Blood ketones Optium c b-ketone 10-strip pack 0–8.0 Abbott = £19.55 PocketScan c1 Blood glucose PocketScan c 50-strip pack 1.1–33.3 LifeScan = £14.41 Prestige c Blood glucose £8.62 Prestigec 50-strip pack 1.4–33.3 Home = £14.51 Diagnostics TRUEonec Blood glucose n/a All-in-one test 50-strip pack with 1.1–33.3 Home strips and meter meter = £14.36 Diagnostics c2 c2 TRUEresult Blood glucose £11.74 TRUEresult 50-strip pack 1.1–33.3 Home = £14.36 Diagnostics TRUEresult twist c 2 Blood glucose £11.74 TRUEresult c 50-strip pack 1.1–33.3 Home = £14.36 Diagnostics 6 Endocrine system TRUEtrack c Blood glucose £8.62 TRUEtrack c 50-strip pack 1.1–33.3 Home = £14.25 Diagnostics WaveSense Jazz c Blood glucose £24.99 WaveSense Jazz c 50-strip pack 1.1–33.3 WaveSense = £14.451. Meter no longer available2. Free of charge from diabetes healthcare professionalsOral glucose tolerance test 6.2 Thyroid and antithyroidThe oral glucose tolerance test is used mainly for drugsdiagnosis of impaired glucose tolerance; it is not recom-mended or necessary for routine diagnostic use whensevere symptoms of hyperglycaemia are present. In 6.2.1 Thyroid hormonespatients who have less severe symptoms and blood 6.2.2 Antithyroid drugsglucose levels that do not establish or exclude diabetes(e.g. impaired fasting glycaemia), an oral glucose toler-ance test may be required. It is also used to establish thepresence of gestational diabetes. The oral glucose tol- 6.2.1 Thyroid hormoneserance test generally involves giving anhydrous glucose75 g (equivalent to Glucose BP 82.5 g) by mouth to the Thyroid hormones are used in hypothyroidism (myx-fasting patient, and measuring blood-glucose concen- oedema), and also in diffuse non-toxic goitre, Hashimo-trations at intervals. to’s thyroiditis (lymphadenoid goitre), and thyroid carci-The appropriate amount of glucose should be given with noma. Neonatal hypothyroidism requires prompt200–300 mL fluid. Anhydrous glucose 75 g may alter- treatment for normal development. Levothyroxinenatively be given as 113 mL Polycal c (Nutricia Clinical) sodium (thyroxine sodium) is the treatment of choicewith extra fluid to administer a total volume of 200– for maintenance therapy.300 mL. In infants and children with congenital hypothyroidism and juvenile myxoedema, the dose of levothyroxine should be titrated according to clinical response, growth assessment, and measurements of plasma thyroxine and thyroid-stimulating hormone. See BNF for Children (section 6.2.1) for suitable dosage regimens.